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ACCP   American College of Chest Physicians  
AIDS   Acquired Immune Deficiency Syndrome 
AIE   Acute Infectious Endocarditis 
ARDS  Adult Respiratory Distress Syndrome 
BSI   Blood Stream Infection 
CFR   Case Fatality Rate 
CI   Confidence Interval 
CNS   Central Nervous System 
COPD  Chronic Obstructive Pulmonary Disease 
DAMPs  Danger Associated Molecular Patterns 
DIC   Disseminated Intravascular Coagulation 
DNR   Do-not-resuscitate 
ED   Emergency Department 
ESBL   Extended-Spectrum Beta-Lactamase 
ESICM   European Society of Intensive Care Medicine 
GCS   Glasgow Coma Scale 
GUI   Genitourinary Infection 
HIV   Human Immunodeficiency Virus 
HR   Hazard Ratio 
ICD   International Classification of Diseases 
ICIP   IntelliVue Clinical Information Portfolio 
ICU   Intensive Care Unit 
IQR   Interquartile Range 
IRR   Incidence Rate Ratio 
LOS   Length Of Stay 
LR   Likelihood Ratio 
MAP   Mean Arterial Pressure 
MODS  Multiple Organ Dysfunction Syndrome 
MRSA  Methicillin Resistant Staphylococcus aureus 
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NPR   Norwegian Patient Registry 
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PAMPs  Pathogen Associated Molecular Patterns 
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SAPS II  Simplified Acute Physiology Score II 
SCCM   Society of Critical Care Medicine 
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SIRS   Systemic Inflammatory Response Syndrome 
SOFA   Sequential Organ Failure Assessment 
SSC   Surviving Sepsis Campaign 
STI   Soft Tissue Infection 
























LIST OF PUBLICATIONS 
 
Paper I 
Siri Tandberg Nygård, Nina Langeland, Hans K. Flaatten, Rune Fanebust, Oddbjørn 
Haugen and Steinar Skrede. Aetiology, antimicrobial therapy and outcome of patients 
with community acquired severe sepsis: a prospective study in a Norwegian university 




Siri Tandberg Nygård, Steinar Skrede, Nina Langeland and Hans K. Flaatten. An 
observational study of community-acquired severe sepsis comparing intensive care 
and non-intensive care patients. Acta Anaesthesiol Scand. 2017 Feb;61:194-204 doi: 
10.1111/aas.12848. PMID: 28058720 
 
Paper III 
Siri Tandberg Knoop, Steinar Skrede, Nina Langeland and Hans K. Flaatten. 
Epidemiology and impact on all-cause mortality of sepsis in Norwegian hospitals: A 
national retrospective study. PLoS ONE. 2017 Nov;12(11):e0187990 doi: 
10.1371/journal.pone.0187990. PMID: 29149187 
 
Reprints of the papers are permitted by the publishers 
 
SUMMARY 
Background: Sepsis develops when the host’s immune response to infection becomes 
dysregulated to such an extent that life-threatening organ dysfunction evolves. Sepsis 
epidemiology is influenced by population characteristics, environmental factors, and 
the occurrence and seasonal spread of pathogens. Thus, local knowledge in this field is 
highly desirable. With this thesis, we aimed to investigate the epidemiology and 




Methods: Paper I and II are based on an observational survey of prospectively 
enrolled patients with community acquired sepsis at Haukeland University hospital in 
Bergen, Norway during the year 2008. Paper III is a retrospective, register based, 
nationwide study on patients hospitalized with sepsis throughout the years 2011 and 
2012. It was performed by use of two databases containing hospitalization and general 
population data respectively; the Norwegian Patient Registry and Statistics Norway.  
Main results: In paper I, the incidence of community acquired sepsis was estimated, 
the underlying infectious sources and microbial etiologies were presented, and the 
precision of clinical diagnostics as well as the compliance with local therapy 
recommendations were evaluated. In paper II, community acquired sepsis patients 
treated in an intensive care unit were compared with a cohort receiving treatment at a 
lower care level. Independent predictors for long-term survival up to five years after 
hospitalization were investigated. In paper III, the demographics of Norwegian sepsis 
patients were explored, the annual population incidence of sepsis was calculated, and 
the fraction of sepsis hospitalizations among all somatic hospital admissions was 
estimated. Finally, the impact of sepsis on all-cause mortality in Norwegian hospitals 
was assessed. 
Conclusion: This thesis demonstrates that sepsis is frequent in Norway, most prevalent 
among the elderly, and significantly more common among men than women. A large 
proportion of sepsis patients never receive intensive care treatment. Areas that need 
improvement are especially the identification and initial handling of less frequent 
infections. Further, the choice of empirical antimicrobial treatment regimens should be 
in greater concordance with local sepsis guidelines, in particular for the oldest patients. 
Sepsis is either the cause of or a contributing factor to a large number of Norwegian 
hospital deaths. Consequently, improvements in treatment could significantly 
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1.1. The history of sepsis 
Of Greek origin, the word sepsis [σηψις] translates to “decomposition of animal or 
vegetable organic matter in the presence of bacteria”. It has been traced back over 
2700 years to the poems of Homer, as a form of the Greek verb sepo (“to rot”), and 
was also used by Hippocrates and Aristoteles in the context of putrefaction [1]. Celsus 
in the 1st century described the clinical signs of inflammation: rubor (peripheral 
vasodilatation), calor (heat), dolor (pain) and tumor (capillary fluid leakage) [2], and 
Avicenna noted a concurrence of fever and putrefaction of blood (septicaemia) a 
millennium later [3]. However, it was not until the 19th century that the pathway of 
discoveries that eventually resulted in today’s comprehension of sepsis truly started 
[4].  
Before the importance of medical hygiene was recognized, operative procedures 
commonly led to severe infections called sepsis thought to be secondary to wound 
putrefaction. First, Semmelweis showed the effect of routine handwashing by 
decreasing mortality from puerperal fever. Around the same time Pasteur discovered 
that putrefaction was caused by bacteria. Lister then introduced the concept of 
antiseptics. In parallel, the term sepsis increasingly appeared in medical academic 
literature [5]. Nevertheless, the perception of the condition was not consistent, and it 
was soon evident that there was a need for a general sepsis definition [6].  
In 1904 Osler was probably first to note the impact of the host’s response in the fatal 
course of severe infection [7]. However, the first linkage of a systemic response to the 
word sepsis came in 1914 by Schottmüller: "Sepsis is present if a focus has developed 
from which pathogenic bacteria, constantly or periodically, invade the blood stream in 
such a way that this causes subjective and objective symptoms. A therapy should not 
be directed against bacteria in the blood but against the released bacterial toxins" [3].  
Antiseptic procedures had tremendous impact on the occurrence of infections in 
relation to medical procedures, but still there was no treatment for sepsis. The 
invention of antibiotics was a milestone, initiated with the discovering of penicillin by 
Fleming and its further development as a therapeutic agent by Chain and Florey in the 
era of World War II [4]. Intensive care medicine evolved in the following decades, 
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with sepsis patients as a large patient population. Lewis was next to further develop 
the understanding of sepsis by marking out that “it is the [host] response … that makes 
the disease” [8]. Some years earlier, Ashbaugh and coworkers had described the Adult 
Respiratory Distress Syndrome (ARDS) [9]. ARDS was thought to be caused by an 
inflammatory reaction, and frequently seen together with sepsis. The 1980s brought 
evidence that this inflammatory reaction was present in the entire body. This led to the 
postulation of a sepsis definition by Roger C. Bone and colleagues that, with some 
modifications, has been valid ever since: "Sepsis can be defined as the systemic 
response to infection” [10, 11]. 
 
1.2. Definitions of sepsis 
1.2.1. Past definitions 
Although the cause of sepsis had been increasingly elucidated and accepted, there was 
no uniform definition that could be applied to identify the affected patients. Research 
on sepsis therefore had poor generalizability. Then, a consensus conference of the 
American College of Chest Physicians (ACCP) and the Society of Critical Care 
Medicine (SCCM) was established, and the first diagnostic sepsis definition was 
published in 1992. Sepsis was presented as infection accompanied by the “systemic 
inflammatory response syndrome” (SIRS) (Textbox 1) [12]. SIRS describes a 
physiologic reaction to harmful stimuli that can also develop in non-infectious 
conditions. “Severe sepsis” was defined as sepsis associated with organ dysfunction, 
hypoperfusion or hypotension, and “septic shock” as severe sepsis with hypotension 
refractory to fluid resuscitation. The use of terms such as “septicaemia” and “septic 
syndrome” were recommended to be abandoned to further promote uniformity. Sepsis, 
severe sepsis and septic shock defined progressive stages of increasing severity, as it 
was proposed that SIRS could evolve into “multiple organ dysfunction syndrome” 
(MODS).  
The new definition was welcomed, and gradually its use as a standard template for 
inclusion in studies increased [13]. However, critics were not far away [14-17]. Some 
appointed the SIRS criteria as too inclusive because they were not restricted to 
infections, while others concluded that they were too restrictive as they were not 
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necessarily fulfilled in cases with infection and organ dysfunction. Consequently, a 
second ACCP/SCCM consensus conference in 2001 (Sepsis-2) was held, resulting in a 
revision of the sepsis criteria [18]. The terms sepsis, severe sepsis, and septic shock 
and their respective definitions were maintained.  However, the criteria were 
considerably expanded with both clinical and laboratory parameters (Textbox 2). 
Overall, the revised sepsis criteria offered a more complete description of the 
condition. Nonetheless, the definition became less distinct and importantly, even more 
dependent on interpretation. Criteria for severe sepsis (hypoperfusion, hypotension and 
organ dysfunction) were at the same time included within the basic sepsis definition, 
and all together the new definition provided just as much confusion as utility. Hence, 
one continued to use the original definition dependent on the SIRS criteria [19-21], 
which in the lack of more specific tests were considered to have many advantages 
[22].  Definitions of organ dysfunction were on the other hand more standardized in 
the new definition, and were thus often applied. After some years, consensus 
definitions for the most frequent infections in septic patients were also developed [23]. 
 
 












Sepsis: infection accompanied by two or more signs of the following SIRS criteria: 
- Temperature  < 36°C or > 38°C 
- Heart rate > 90 per minute 
- Respiratory rate > 20 per minute or PaCO2 < 4.3 kPa in arterial blood gas analysis 





Textbox 2. Sepsis criteria from 2001 [18] 
 
 
1.2.2. The present definition: Sepsis-3 
The formal sepsis definition was left unaltered for many years, although SIRS criteria 
were still subject to criticism from clinicians [24, 25]. As extensive progress in the 
understanding of sepsis’ pathophysiology was made, there was an increasing demand 
for the term sepsis to encompass a distinct entity from infection, both of which 
commonly influence the clinical signs of inflammation [26]. A Task Force of 19 
critical care, infectious disease, surgical and pulmonary specialists from the European 
Society of Intensive Care Medicine (ESICM) and the Society of Critical Care 
Medicine (SCCM) was established, and the novel Sepsis-3 definition was published in 
February 2016 [27]. Sepsis was defined as “life-threatening organ dysfunction caused 
by a dysregulated host response to infection” and the term “severe sepsis” was found 
superfluous. It was recommended  that  organ dysfunction should be defined according 
Sepsis: documented or suspected infection and some of the following:  
- General parameters  
Fever (core temperature >38.3°C)  
Hypothermia (core temperature <36°C)  
Heart rate >90 per minute or >2 standard deviations (SD) above the normal value for age  
Tachypnea  
Altered mental status  
Significant edema or positive fluid balance (>20 ml/kg over 24 h)  
Hyperglycemia (plasma glucose >120 mg/dl or 7.7 mmol/l) in the absence of diabetes  
- Inflammatory parameters  
Leukocytosis (white blood cell count >12x109/l)  
Leukopenia (white blood cell count <4x109/l)  
Normal white blood cell count with >10% immature forms  
Plasma C reactive protein>2 SD above the normal value  
Plasma procalcitonin >2 SD above the normal value  
- Hemodynamic parameters  
Arterial hypotension (systolic blood pressure <90 mmHg, mean arterial pressure (MAP) <70, 
or a systolic blood pressure decrease >40 mmHg in adults or <2 SD below normal for age)  
Mixed venous oxygen saturation >70%  
Cardiac index >3.5 l/min/m2  
- Organ dysfunction parameters  
Arterial hypoxemia (PaO2/FiO2 <300 mmHg or <40 kPa)  
Acute oliguria (urine output <0.5 ml/kg/h for at least 2 h)  
Creatinine increase ≥0.5 mg/dl or ≥45 μmol/l  
Coagulation abnormalities (international normalized ratio >1.5 or activated partial 
thromboplastin time >60 s)  
Ileus (absent bowel sounds)  
Thrombocytopenia (platelet count <100,000/μl)  
Hyperbilirubinemia (plasma total bilirubin >4 mg/dl or 70 μmol/l)  
- Tissue perfusion parameters  
Hyperlactatemia (>3 mmol/l)  






to the previously established scoring system Sequential Organ Failure Assessment 
(SOFA) score, used in the critical care setting (Table 1) [28]. An acute change in total 
SOFA score ≥ 2 points is to be understood as organ dysfunction. Acknowledging the 
comprehensiveness of the SOFA score, the Task Force also suggested a new screening 
tool suitable for use outside the intensive care unit (ICU), called the quick SOFA 
(qSOFA), in order to identify patients at high risk of death or need for intensive care 
treatment. It consists of alteration in mental status, systolic blood pressure 
≤100mmHg, and/or respiratory rate ≥22/min and is independent on laboratory tests. 
Fulfillment of qSOFA score parameters should stress clinicians to further investigate 
for organ dysfunction and initiate appropriate measures. Finally, the definition of 
septic shock was also updated in the Sepsis-3 definition. This condition is now 
recognized as vasopressor requirement to maintain MAP ≥65mmHg despite adequate 
volume resuscitation, accompanied by a serum lactate level >2 mmol/l. 
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or epinephrine ≤0.1 
or norepinephrine ≤0.1a 
 
Dopamine >15 or 
epinephrine >0.1 
































Abbreviations: FiO2, fraction of inspired oxygen; PaO2, partial pressure of oxygen; resp., respiratory; MAP, 
mean arterial pressure; CNS, central nervous system; GCS, Glasgow Coma Scale. 
aCatecholamine doses are given as μg/kg/min for at least 1 hour. 
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1.3. An overview of sepsis pathophysiology  
Usually, a localized infection initiates a limited, protective inflammatory host reaction 
which serves to control pathogen invasion and initiate tissue repair. In sepsis, this 
reaction has become generalized, affecting organ systems remote from the infectious 
focus [29]. Exhaustion of inflammatory responses, characterized by apoptosis and 
hyporesponsiveness of immune cells, eventually results in immune suppression. The 
pro- and anti-inflammatory reactions occur simultaneously and their magnitude are 
modified by both host and pathogen factors. Importantly, sepsis patients may follow 
disease courses where either a pro- or anti-inflammatory state interchangeably 
dominates. To add even more complexity, different reactions occur at local, regional 
and systemic levels.  
The inflammatory response is initiated by receptors known as pattern recognition 
receptors (PRRs). These are e.g. members of the Toll-like receptor (TLR) family, and 
are activated upon recognition of conserved pathogen associated molecular patterns 
(PAMPs) expressed by the causal microbes. When host tissue is damaged, PRRs can 
additionally react via endogenous structures released from dying cells, called danger 
associated molecular patterns (DAMPs). DAMPs are mimics of microbial PAMPs, and 
both PAMPs and DAMPs promote the inflammatory reaction in sepsis (Figure 1) [30]. 
Immune suppression results from defect functions of immune cells, inhibited pro-
inflammatory gene transcription, and neuroendocrine regulation. There is also an 
imbalanced activity of coagulation and anticoagulant mechanisms that may result in 
concomitant microvascular thrombosis and bleeding. Furthermore, damage to the 
vascular endothelium and its barrier function, caused by a loss of function of cell-to-
cell tight junctions, leads to capillary leak and loss of intravascular volume to 
interstitial fluid. Following is tissue hypoperfusion and edema which may result in a 
decrease in cardiac output. This may be aggravated by suppression of myocardial 
contractility and loss of vascular tone due to high levels of inflammatory mediators 
including nitric oxide, critically affecting organ perfusion. Cardiovascular compromise 
due to sepsis is therefore multifactorial, but recognized primarily as hypotension [31]. 
Damage to the alveolar-capillary membrane causes impaired lung function through 
altered vascular permeability causing excess fluid in both alveoli and the interstitium 
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(pulmonary edema) [32]. Consequences are impaired gas exchange, increased 
pulmonary arterial pressure and decreased compliance. Respiratory dysfunction in 
sepsis is classically manifested as ARDS, defined as acute onset hypoxemia with chest 
imaging showing evidence of bilateral opacities of noncardiac origin [33]. Besides, in 
sepsis oxygen delivery may be further lowered due to reduced red-cell deformability 
and metabolic events. Renal dysfunction demonstrates as increasing s-creatinine level 
and decreased urine output that may require renal-replacement therapy [29]. 
Dysfunction of the CNS is typically evident as delirium or obtundation without focal 
lesions on imaging studies. The aforementioned four organ systems: cardiovascular, 
respiratory, renal, and CNS, most commonly show evidence of dysfunction in sepsis 
patients. However, all parts of the body can be affected, and sepsis may present with 
paralytic ileus, disseminated intravascular coagulation (DIC), elevated liver enzymes, 
altered glycemic control, the euthyroid sick syndrome, adrenal dysfunction, myopathy 
as well as critical illness polyneuropathy [29]. 
Historically, organ dysfunction in severe sepsis and septic shock was thought in simple 
terms as synonymous with increasing tissue hypoperfusion and the following 
impairment in tissue oxygenation. Still, organ dysfunction can occur in the absence of 
apparent macrovascular abnormality (hypotension) [32]. Pursuing the theory of 
deficient oxygenation, this has been explained by impairment in regional perfusion 
second to redistribution of intraorgan blood flow with shunting away from nutrient 
capillaries as well as a constricted/obstructed microcirculation. However, the process 
behind the development of organ dysfunction in sepsis is increasingly understood as 
far more complex, and probably only partially elucidated at this point. 
Histopathological examinations that have shown low levels of cell injury (necrosis and 
apoptosis) [34, 35], as well as observations of dysfunctional or even failing organs that 
recover relatively fast in survivors of sepsis, have been interpreted as evidence for co-
existence of other mechanisms [32]. In fact, both animal models and clinical studies of 
sepsis have been performed without observation of cellular hypoxia [36-38]. The 
mitochondria are by many authorities considered as a key element in this matter [39]. 
Oxidative stress caused by inflammation leads to inhibition of mitochondrial complex 
activities with resulting failure of energy production in exposed cells and structural 
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damage to e.g. mitochondrial DNA. Injured structures serve as alarmins in the 
extracellular environment that can activate immune cells and cause further injury. 
Theories of a cellular adaptive response to such events, i.e. only processes necessary 
for cell survival are maintained on behalf of specialized, organ specific functions, 
DNA replication, and cell cycling, have long been circulating [40]. Further details are 
however beyond the scope of this thesis.  
 
 
Figure 1. The host response to sepsis. Importantly, direction, extent, and duration of 
the septic response is determined by both host factors, such as genetic composition, 
age, comorbidity, and medication, and pathogen factors, including microbial load and 
virulence. Abbreviations: PRR, pattern recognition receptors; LPS, lipopolysaccharide; LTA, 
lipoteichoic acid; HSP, heat shock protein; HMGB-1, high mobility group box-1 protein; IL, 
interleukin; MRP8/14, migration inhibitory factor-related protein-8/14; NETs, neutrophils 
extracellular traps; T, T lymphocytes; B, B lymphocytes; DC, dendritic cells; Tregs, regulatory T 
lymphocytes.  




1.4. Treatment of sepsis 
Sepsis is a medical emergency requiring effective and prompt treatment once 
identified. Because of the heterogeneity of the affected patients, the underlying 
infections and the clinical presentation, it may seem inconvenient to have a standard 
way of care. However, several investigations have shown that time to antibiotic 
treatment and resolution of shock is of particular importance for hospital survival [41-
43]. Therefore, successful management of affected patients mainly relies on early 
recognition, and there is broad consensus that therapy recommendations should be 
founded in clinical practice guidelines [44]. The Surviving Sepsis Campaign’s (SSC) 
international guideline for management of (severe) sepsis and septic shock has been a 
valuable template since they were first published in 2004 [45]. The 4th revision 
appeared in 2016, and has influenced many local guidelines [46]. The current 
recommendations for sepsis therapy at Haukeland University Hospital, apart from anti-
infective measures, are presented in Textbox 3. 
Treatment of sepsis can be divided into two categories based on the following goals:  
1. Eradication of the underlying infection, and 2. Supportive care to treat and prevent 
further development of organ dysfunction(s). In many cases the latter requires 
admission to an ICU. The first goal includes optimal sampling to identify causal 
pathogens and administration of appropriate antimicrobial therapy, as well as operative 
procedures in order to achieve control of the infectious source when appropriate. The 
new SSC international guideline recommends initiation of intravenous antibiotic 
therapy within one hour after sepsis has been diagnosed [46]. Initial antimicrobial 
therapy is most often empirical, and recommendations should be customized based on 
microbiological surveillance data at local level [47]. The recommended treatment 
regimens for sepsis in Norway are outlined in the national guideline for antimicrobial 
therapy issued by The Norwegian Directorate of Health [48]. Indiscriminate use of 
broad-spectrum antibiotics is undesirable [49], and identification of a plausible 
pathogen should result in adjustment to narrow-spectrum antibiotics when applicable 
[50]. Regarding goal number two, actions to be taken depend on both the pre-existing 
and the current condition of the patient. Hemodynamic resuscitation with intravenous 
fluids, and supply of vasoactive drugs when necessitated, is of immediate priority.  
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However, there are important exceptions in fluid challenge therapy, such as end-stage 
renal disease or congestive heart failure.  
During the past few decades there has been an extensive search for new sepsis 
therapies, in particular in the field of immune-modulating drugs. Recombinant human 
activated protein C was available for approximately a decade, but eventually 
withdrawn in 2011 as it failed to prove beneficial effect on survival in a control study 
[19]. Despite the advancement in the understanding of sepsis’ pathogenesis, virtually 
all approaches have thus failed, and to date no specific anti-sepsis treatment exists.  
 
Textbox 3. Overview of the current recommendations for sepsis therapy at 
Haukeland University Hospital apart from anti-infective measures 
 
Fluid therapy 
- intravenous crystalloids (e.g. Ringer’s Acetate), usually 20-30 ml/kg within the first four hours 
 
Vasoactive medications 
- norepinephrine is the first-choice vasopressor, and should be administered through a central 
venous catheter. 
- an arterial catheter should be placed as soon as practical in all patients requiring vasopressors; 
target systolic blood pressure > 100 mmHg (or MAP > 65 mmHg). 
- assessment of the hemodynamic response also includes monitoring of hourly urine output and 




- in the case of mild respiratory dysfunction: nasal or facial mask supply of oxygen 2-10 l/minute.  
- in more severe cases of respiratory failure: use of non-invasive or invasive ventilation support 
 
Treatment of renal failure 
 - urinary catheter insertion, thoroughly monitoring of diuresis (hourly urine output) 
 - discontinue and/or restrict use of medications with negative influence on renal function 
 - monitor levels of potassium, and examine for metabolic acidosis and fluid overload 
- if renal replacement therapy is required in patients with septic shock, continuous therapy is 
preferable to facilitate the management of fluid balance  
 
Blood products 
 - red blood cell transfusion: when hemoglobin decreases < 7.0 g/dl 
 - platelet transfusion: when platelet counts are < 10 × 109/l  in the absence of bleeding; < 20 ×  
109/l  if significant risk of bleeding. Higher platelet counts (< 50 × 109/l ) in case of active bleeding, 
surgery, or invasive procedures 
- fresh frozen plasma: should be considered in cases with disseminated intravascular coagulation, 
active bleeding and need of large amounts of intravenous fluids 
 
Other  
- insulin infusions: when blood glucose levels are > 10.0 mmol/l, with a target level of 6.6 to 10.0 
mmol/l. Blood glucose levels should be monitored frequently 
- corticosteroids: intravenous hydrocortisone at a dose of 50 mg x 4 per day in cases with unstable 
septic shock despite adequate fluid resuscitation and vasopressor administration 
- stress ulcer prophylaxis: only administered  in cases with risk for gastrointestinal bleeding 
- venous thromboembolism prophylaxis: low-molecular-weight heparin if no contraindications exist 
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1.5. Epidemiology of sepsis: current findings and limitations 
1.5.1. Reviewing studies on sepsis epidemiology 
Before the first publishing of international consensus definitions of sepsis, research 
was encumbered by poor generalizability of study results.  Today, most old data are of 
limited relevance and results published earlier than 1992 are therefore excluded from 
this work. Because the focus of the original papers in this thesis is sepsis with organ 
dysfunction (formerly designated severe sepsis, now sepsis), the following section is 
limited to studies providing data on this condition. We adhere to the term sepsis cf. the 
most recent definition. To facilitate the review of existing sepsis literature, important 




The formulation of a consensus definition laid a foundation for the use of standard 
inclusion criteria in studies of sepsis. However, the standardization was only valid to a 
limited extent, as there was still need for subjective interpretation. Questions such as 
what is the definition of a clinical suspected infection and which microbes qualify as a 
causative etiology, or what should be cut-off levels for presence of organ dysfunctions, 
were problems left to overcome for each study.  
 
1.5.1.2. Methodology 
Studies providing epidemiological data on sepsis can in general be divided into three 
categories on the basis of methodology (A-C). 
 
A. Retrospective code-based studies 
Based on national or regional databases, these studies aim to provide population-level 
epidemiological data. To identify sepsis, various sets of diagnostic codes according to 
International Classification of Diseases 9th or 10th revision (ICD-9 or -10) diagnostic 
codes for infection, sepsis or septic shock, and organ dysfunctions are extracted from 
registries. Hence, the quality of medical diagnostic coding, as well as the general 
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ability of physicians to identify sepsis in their work are determining factors for the 
quality and reproducibility of results. For a long time, specific codes for SIRS and 
sepsis with organ dysfunction (except for septic shock) did not exist. Data abstraction 
was then based on the combination of codes for clinical infection category and/or 
sepsis categorized by use of microbial etiology, plus codes for organ dysfunction(s) or 
procedures indicative of the latter. A major limitation is that codes for organ 
dysfunctions cannot be verified to have been caused by sepsis rather than another co-
occurring condition. The introduction of the codes for SIRS without and with organ 
dysfunction (the year 2003 in the U.S., the year 2009 in Norway) did not fully solve 
this problem, as they are inconsistently used [51].  
 
B. ICU-based studies 
These studies are confined to intensive care units and are performed primarily to 
estimate the occurrence of sepsis, either in terms of prevalence or incidence, or both. 
In general, results are impaired because of a limited patient selection. Many patients 
with sepsis have a disease course that does not require intensive care therapy, while 
others are omitted from such facilities due to pre-defined restrictions in care (e.g. do-
not-resuscitate (DNR) orders). Some of the studies are retrospective studies based on 
large ICU-registries. The majority are however based on prospective enrollment, 
enabling a systematic process of clinical case inclusion with the opportunity to identify 
all patients with sepsis admitted during a given study period. A number are very short 
lasting cross sectional surveys, down to point prevalence studies determined in the 
span of one day [52, 53]. This makes it possible to perform large multicenter studies. 
Generalization of the results has important limitations however, given variations in 
seasonal occurrence of infections, focus of infection, microbiological etiology and 
outcome of sepsis [54-56]. Besides, organ failures may develop later in the disease 




C. Observational studies with inclusion of non-ICU patients 
To overcome many of the abovementioned problems, these studies focus on the group 
of sepsis patients not receiving intensive care, either by exclusive descriptions of this 
cohort or with intention to cover all sepsis cases in one study. As this task is very 
comprehensive, their main limitation is related to site of enrollment. They are mostly 
confined to single hospitals.  Frequently substitutes for hospital-wide inclusion are 
used, either by selecting a few floor units to survey, or by restricting study enrollment 
to an Emergency Department (ED). The latter is troublesome if there is no follow-up 
beyond the ED, as suspected sepsis may not be verified later on during the hospital 
stay.  
 
Two epidemiological studies have recently been published that do not fit in any of the 
aforementioned categories. The first is a retrospective survey based on a registry 
covering the use of intravenous antibiotics in a Swedish hospital [57]. The second is a 
large Chinese investigation in which all admission records in a subdistrict of Beijing 
were manually reviewed [58]. Furthermore, clinical intervention trials could have been 
included as a fourth category. They provide characterizations of the enrolled patients 
with sepsis and have to some degree influenced epidemiological viewpoints of the 
condition. However, as they were not designed as epidemiological research, their 
results are not presented herein. 
 
1.5.1.3. Societal impact on study results 
Several differences in the underlying general population and the society influence the 
risk of developing sepsis, as well as its outcome. Some examples are age, sex, race, 
socioeconomic conditions, health-care systems including ICU capacity and threshold 
for admittance, types of infections, occurrence of drug-resistant microbes, and 
prevalence of comorbidities. Expectedly, the largest discrepancies are seen between 
high-income countries versus low-income and middle-income countries [59]. There 
are however also significant differences among high-income societies [60-63], even 
within single countries, that limit the transferability of study results. Perhaps most 
relevant is institutional characteristics [52, 64, 65]. There are differences in both the 
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occurrence and severity of sepsis between local versus referral hospitals, especially in 
terms of ICU facilities. Consequently, one should evaluate not only whether a study is 
of single or multicenter origin, but also the type of participating centers. This leads to a 
fundamental issue of all sepsis studies, namely that they only include the hospital-
treated cases. Because most studies of sepsis are from high-income countries, this is 
primarily an aspect in the group of multimorbid, older persons living in nursing homes 
or similar facilities. They often have a predetermined decision not to be hospitalized in 
case of acute illness. It is therefore evident that all aspects of sepsis, including its true 
burden on society, cannot be determined through existing hospital-oriented 
epidemiological studies only. 
 
1.5.1.4. Follow-up 
Most studies use outcome at the end of hospitalization or 28 days after inclusion as 
their primary endpoint. Long-term mortality is however significantly higher in patients 
with sepsis compared to the rest of the population [66]. This is another crucial point to 
be aware of in the evaluation of sepsis epidemiology.  
 
To sum up, studies of sepsis epidemiology have several problems to overcome: a) 
study design, b) sepsis definition, c) exclusion criteria, d) duration, e)  targeted 
population (national, regional, multi-, or single-center study), f) level of treatment 
(only ICU and/or non-ICU treated patients), g) seasonal variation, h) hospital admitted 
or ICU-treated incidence (and not population-wide), and i) length of follow-up. With 
this in mind, a summary of previous studies of the epidemiology of sepsis is presented 
in Table 1. There is a great variance in the results obtained in terms of occurrence and 
outcome. This underscores that sepsis is a condition with particular need for local data. 
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Sepsis is indisputably a frequent condition. Recent calculations indicate a population-
incidence in the range of 100 to 350 per 100 000 inhabitants in high income countries 
(Table 1). In 2013, sepsis was ranked as the most expensive medical condition in a 
national investigation of inpatient hospital costs in the U.S. [126]. Eligible studies only 
include the hospital admitted fraction of patients and there are no explicit studies on 
sepsis outside the acute health care system. However, sepsis was the most common 
reason for hospitalization of nursing home residents in the U.S. in the year 2011, 
indicating a considerable occurrence in such facilities that contributes to the societal 
burden of sepsis [127]. When hospitalized, sepsis patients account for 1 to 2 % of all 
somatic admissions [58, 70, 74, 75, 77, 82, 117, 123]. The fraction of patients with 
sepsis that are not treated in an ICU is around 50% (Table 1). In ICUs, patients with 
sepsis constitute around 10 to 25 % of cases at any given time [77, 91, 94, 108, 111, 
113, 123]. 
Traditionally, results from Scandinavia have indicated a lower occurrence than in most 
of Europe and the U.S. However, as there is a scarcity of previous results and the 
methods applied in these studies differ, firm conclusions cannot be made at this point. 
Adding to this uncertainty, a Danish prospective study from 2011 has recorded one of 
the highest previous estimates globally (Table 1), even though it was confined to  
community acquired sepsis [55]. There is only one previous epidemiological 
investigation of sepsis in Norway, a retrospective study from the year 1999 [67].  
Table 1 demonstrates that the reported occurrence of sepsis has increased during the 
past decades. This observation is confirmed by studies on time-related trends in sepsis 
epidemiology [74, 76, 77, 79, 85, 93, 110].  The reason for this is probably 
multifactorial. In addition to changes in health care and aging of the population in 
general [128], diagnostic coding patterns and  physicians’ awareness as well as 
subjective perception of sepsis seem to have a substantial  impact [129, 130], 







Figure 2. Hospitalizations for which certain infection codes were listed as a primary 
diagnosis, 2003–2011. 






Figure 3. Distribution of classification of five case vignettes of patients with suspected 
or confirmed infection and organ dysfunction, done by 94 practicing intensivists. 
 Modified from [130], no permission needed (http://creativecommons.org/licenses/by/4.0/). 
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1.5.3. Demographics  
Sepsis is most common among the elderly. Reasons for this are immunosenescence, 
predisposing chronic diseases, repeated hospitalizations and/or residence in long-term 
care facilities, malnutrition, age-related physical loss including sarcopenia and 
cognitive impairment [131]. Mean age of affected patients have increased during the 
past decades [74, 93], and has passed 70 years in the most recent reports in Table 1. It 
has been shown that sepsis occurs more often in men than women in studies reporting 
age-specific incidences [70, 75, 77]. Many researchers have also found racial 
disparities in sepsis, the majority reporting a higher occurrence and a lower mean age 
among African-Americans compared to whites in the U.S.  [80, 123, 132, 133]. 
However, the debate is still ongoing as these results are from retrospective surveys, 
whereas a recent longitudinal cohort study investigating community acquired infection 
could not confirm previous findings [134]. It has been postulated that the observed 
gender and racial disparities are influenced by cultural and socioeconomic differences 
that affect health behavior, risk for comorbidities, and access to or quality of medical 
care. Furthermore, a role for biological factors such as genetics, immune response and 
sex hormones has been suggested [59, 131, 132].  
 
1.5.4. Comorbidities 
Most patients with sepsis carry risk for contracting severe infection because of 
preexisting and significant comorbidity.  Many categories of comorbidities render the 
host more susceptible to a given pathogen or type of infection, and influence outcome 
[131]. Most studies that offer crude data on the overall frequency of patients with 
comorbidities report that it affects around 50% of sepsis cases [74, 77, 88, 96, 99, 110, 
133]. However, presence of comorbidities is highly dependent on the definitions used 
and patient population features. Accordingly, both much lower figures as well as 
frequencies up to 90% have been reported [58, 89, 93, 94, 135]. Although the 
estimates vary widely, it is possible to outline some general trends. Overall, 
cardiovascular disease is the most frequent preexisting condition in patients with 
sepsis. Prevalence of hypertension is substantial if this category is specified; 35-57% 
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[58, 85, 91, 117, 122]. Furthermore, coronary artery disease and congestive heart 
failure is prevalent [58, 74, 75, 81, 85, 92, 122]. The presence of diabetes mellitus is 
considerable (16-27%) [58, 81, 85, 91, 98, 117, 133].  Occurrence of malignancies is 
in the range of 10-30%, and studies that specify the proportion of patients with 
metastatic cancer are uniformly between 4-8% [58, 74, 75, 77, 88, 96, 122, 133].  
From less than 10% to 25% of patients with sepsis have been found to have chronic 
respiratory disease, yet the respiratory tract is the most common focus of infection in 
sepsis [58, 75, 77, 81, 85, 88, 91, 117, 122, 133]. Chronic renal disease is less 
frequent, while chronic liver disease is rare [74, 77, 81, 91, 92, 117, 122, 133]. The 
criteria for categorizing patients as immunosuppressed vary between studies.  
Consequently, substantial variation is found in the results (6-39%) [88, 91, 92, 96, 99, 
117, 136]. HIV positive, limited to patients with AIDS or not, constitute between 1-6% 
of patients in Southern Europe and the U.S [74, 75, 77, 81, 96, 99, 122]. Abuse of 
alcohol is not often specified, but was frequent in a Finnish ICU cohort (26%), while 
reports from other Nordic countries, Wales and Spain indicate lower numbers (5-11%) 
[55, 89, 91, 99, 117, 137]. Cognitive impairment (dementia) is specified in two studies 
only, both at 6% [66, 117].  
1.5.5. Focus of infection 
Pneumonia is the most prevalent infection in hospitals in high income countries 
(Figure 2).  Expectedly, the most common focus of infection in sepsis is the lower 
respiratory tract (Table 2). Second are genitourinary infections (in retrospective 
studies) and abdominal infections (in ICU settings), followed by soft tissue infections 
(STIs). Infections in the central nervous system and acute infectious endocarditis 
(AIE) are rare causes. The fraction of cases with primary blood stream infections 
(BSIs) is variable (2-20%). Most reports of the proportion of patients with community 
acquired compared to nosocomial contracted infections are close to 50%, within the 







Table 2. Identified foci of infection (%) in selected studies of sepsis 
 
Studies including both ICU and non-ICU patients  
Cate-
gorya 
Country N = RTI Abd GUI STIb BSIc CNS AIE Device Otherd Ref. 
A Denmark 212 25 9 36 11e 5 3 1 - 10 [68] 
A Spain 82 300 33 11 37 4 - <1 2 1 38 [75] 
A U.S. 381 878 39 8 15 8 20 <1 <1 1 7 [133] 
A U.S. 192 980 44 9 9 7 17 <1 <1 2 11 [77] 
C Denmark 1 071 68 10 25 4e 2 <1 <1 - 8 [55] 
















Other U.S. 49 331 40 9 27 - - - - - 23 [138] 




Studies including ICU patients only  
Cate-
gorya 
Country N = RTI Abd GUI STIb BSIc CNS AIE Device Otherd Ref. 
A England 248 864 45 31 5 5 - 2 3 - 9 [94] 
B Sweden 127 21 20 13 7 - - - 6 g 33 [88] 
B Finland 470 43 32 5 10 - 2 2 1 10 [91] 




134 47 34 2 7 2 1 - - 7 [98] 
B Germany 1 503 52 29 13 10 2 2 2 3 6 [95] 
B Germany 415 63 34 7 9 - - - - - [52] 
B Poland 4 999 28 49 6 6 8 3 - 3g 5 [101] 
B France 546 49 24 5 7e 5 1 2 3 6 [96] 
































691 52 19 6 10 10 3 1 3 c 2 [108] 
 
Abbreviations: RTI, respiratory tract infection; Abd, abdominal infection; GUI, genitourinary infection; STI, soft 
tissue infection; BSI, blood stream infection; CNS, central nervous system infection; AIE, acute infectious 
endocarditis, Ref., reference; vs, versus 
a Study category A, B, C or other cf. section 1.5.1.2. b Including surgical wounds if specified c Proportion of 
patients with presumed primary bacteriemia d Including unknown focus of infection e Including bones and joints 
f Patients identified using the Sepsis-2 versus Sepsis-3 definition respectively g Including central venous catheters 
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1.5.6. Microbial etiology and antimicrobial resistance 
Even in prospective investigations, the microbial etiology of sepsis is detected in only 
2 out of 3 patients [88, 89, 95, 96, 99, 108, 113, 114, 136, 139]. Equivalent detection 
rates are however the norm for hospitalized patients with severe infections in general 
[140]. The proportion of patients with detected bacteriemia is with few exceptions 
between 25-40% [88, 91, 95, 101, 113, 141]. Sepsis is first and foremost associated 
with bacterial infections, but fungi, viruses and parasites are all eligible pathogens. 
Viruses, especially influenza strains, may have additional impact as they are associated 
with secondary bacterial infections [142]. The detection of various pathogens in sepsis 
patients is dependent on geographical location, the level of care, the distribution of 
infections, seasonal variation and the quality of microbiological diagnostic services 
[47]. During the 1990s and first years after the millennium, Gram-positive bacteria 
were somewhat more frequently encountered than Gram-negative bacteria in sepsis 
patients [47, 91, 96, 108, 114]. In more recent years, the presence of Gram-negative 
bacteria has increased, together with the proportion of patients with fungal infections 
[74, 89, 99, 101, 133, 136, 140, 143]. This is possibly a reflection of advances in 
health care that inevitably leads to increasing numbers of frail patients more prone to 
these etiologies. Enterobacteriaceae, mainly Escherichia coli but also Klebsiella 
species, are the most important Gram-negative causes of sepsis. The most frequently 
observed Gram-positive microbes are Staphylococcus aureus, Streptococcus 
pneumoniae and Enterococcus species [99, 101, 108, 140, 144]. The presence of 
anaerobic bacteria is generally found to be low [74, 113, 140]. The occurrence of 
pathogens with relevant antimicrobial resistance is substantially different in various 
parts of the world. In a global perspective, the prevalence of resistant bacteria is low in 
the Nordic countries [47, 140, 145-147]. It is not well documented whether these 
pathogens are seen more frequently in sepsis compared to infection in general. 
Nevertheless, it is important to notice that the official Norwegian surveillance program 
for antimicrobial resistance (NORM) has recorded a substantial increase in the relative 
proportion of such microbes during the last decade [147]. In their last report (the year 
2016), nearly 6% of Escherichia coli and 5% of Klebsiella species in investigated 
blood cultures were extended-spectrum beta-lactamase (ESBL)-producing, 17% of 
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Escherichia coli were non-susceptible to ciprofloxacin, and nearly 7% to gentamicin 
[10]. Furthermore, 1% of Staphylococcus aureus were methicillin resistant, 0.5% of 
Enterococcus species were vancomycin resistant (Van A or Van B positive), and 0.3% 
of Streptococcus pneumoniae penicillin resistant, while nearly 6% of the latter showed 
non-susceptibility to penicillin. Candida albicans isolates were all susceptible to 
fluconazol. However, the occurrence of bacteria with troublesome resistance is still 
low in Norway compared to most similar settings. This is reflected in the 
recommended empirical treatment regimens for sepsis in the national guideline for 
antimicrobial therapy; for instance the recommended choice of treatment when the 
infectious focus is considered unknown is benzylpenicillin and gentamicin [46].  
 
1.5.7. Organ dysfunction 
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host 
response to infection.  In ICUs, as many as 80-90% of patients have cardiovascular 
dysfunction [56, 60, 91, 92, 94], but figures closer to 50% are also reported [52, 95, 
99, 110]. The proportion with respiratory failure is commonly found to be around 70% 
among ICU-treated sepsis patients in Europe [91, 94, 95, 99], while results from the 
U.S. usually are lower [60]. In the majority of studies targeting ICU cohorts, renal 
failure is seen in 40-50%, followed in occurrence by metabolic (usually around 40%), 
CNS (12-44%), and hematologic dysfunction (around 20-30%), while hepatic 
dysfunction is more rare (2-14%) [52, 60, 91, 92, 94, 95, 99]. Studies including 
patients outside ICUs have in general lower occurrences of most organ dysfunctions. 
Besides, a smaller fraction of patients with multiple organ dysfunctions is reported 
(14-55%) [55, 57, 74, 75, 79, 81, 82, 86, 141] than in studies restricted to ICU patients 
(70-90%) [56, 68, 86, 92-94, 99, 101]. Different from explicit ICU-studies is that renal 
failure is often most prevalent [75, 81, 82, 85]. Besides, a more equal occurrence of 
renal, respiratory and cardiovascular dysfunction is seen, often affecting 
approximately 50% of patients each [68, 74, 81, 82, 85, 136, 141]. However, there are 
exceptions. Most noticeable is perhaps the low number of cases with cardiovascular 
dysfunction reported from a prospective study of community acquired sepsis in a 




Despite a notable decrease in recent years, hospital mortality from sepsis is still high 
[74, 81, 82, 85, 94, 110]. The most recent SSC guideline states that sepsis kills one in 
four patients [46]. Since outcome is dependent on a variety of factors, there are 
however large deviations in the results presented in Table 1. For instance, several of 
the more recent retrospective studies have estimated a mortality rate close to 15% [75, 
82, 85, 136, 148], whereas other similar studies have found that one in every two or 
three sepsis patients died [68, 70, 71, 74, 81, 82]. The mortality rate in prospectively 
registered ICU cohorts is usually found to be higher than in prospective studies 
originating in part or completely from outside the ICU environment [115, 117, 123, 
149]. Sepsis is also associated with negative long-term effects. Hospital survivors have 
been found to have increased mortality for up to ten years after hospitalization, suffer 
from cognitive impairment and functional disability, and many have decreased quality 


















2. AIMS OF THE THESIS 
 
While the number of international studies on sepsis was rapidly increasing at the 
starting point of our current work, there was only a single study on sepsis 
epidemiology in Norway from 1999 available. Given the lack of contemporary local 
and national data, we decided to investigate different aspects of sepsis by use of two 
different, complementary approaches. The principal aim of the thesis has been to 
assess the epidemiology of sepsis, to characterize the patient cohort and to describe 
care and outcome of patients with sepsis treated in Norwegian hospitals. Furthermore, 
international studies were mainly focused towards the ICU-treated cohort of sepsis 
patients.  At the same time, many patients in our institution with sepsis were treated 
outside the general ICU.  Therefore we identified a need for characterizing and 
evaluating the entire hospital-treated sepsis population locally. 
2.1. Main objective 
 to provide epidemiological  data for sepsis in Norway 
 to investigate population incidence and hospital occurrence, etiology, patient 
features, location of care, treatment and outcomes 
2.2. Secondary objectives 
 to evaluate time-related trends in occurrence and outcomes of sepsis in Norway 
 to evaluate the diagnostic precision and quality of care for patients with sepsis 
in a Norwegian setting 
 to study the features of the population of sepsis patients treated outside 
intensive care in our hospital 
 to compare characteristics, treatment intensity and outcomes in the ICU-treated 
sepsis cohort compared to the non-ICU treated cohort 
 to evaluate the use of recommended empirical antimicrobial therapy 
 to explore prognostic risk factors for in hospital and long-term mortality among 
sepsis patients 




3. MATERIALS AND METHODS 
3.1. Summary of Methods Paper Ι and II 
Paper I and II are based on a one year prospective, case defined observational study of 
patients hospitalized with community acquired sepsis at Haukeland University 
Hospital in the period from January 1st through December 2008. Enrollment took 
place in the following units: (1) a 10-bed general ICU at the Department of 
Anaesthesia and Intensive care; (2) a 12-bed combined ICU/non-ICU ward at the 
Department of Cardiology, composed of four fully equipped ICU beds and eight 
surveillance beds; and (3) a 13-bed ward at the Division of Infectious Diseases, 
Department of Medicine. All subjects transferred from the emergency department 
(ED) to any of the three units were screened to see if they fulfilled the consensus 
criteria for sepsis used at that time, with some minor modifications of the diagnostic 
criteria for organ dysfunctions which are specified in section 5.1.5. Patients older than 
15 years of age hospitalized due to community acquired infection, including patients 
transferred from affiliated hospitals, were included if they developed sepsis within 24 
hours of admission to the primary institution. We excluded patients if they had been 
hospitalized within the preceding 30 days to avoid inclusion of nosocomial infections. 
In patients with multiple sepsis admissions during the study year, only the first sepsis 
episode was included. Patients were evaluated for eligibility by use of admission 
records, patient charts and inquiries with senior physicians at the respective wards. 
Clinical data were registered prospectively until hospital discharge or in-hospital 
death, using predefined case report forms. Data from the ED and from affiliated 
hospitals before transfer were registered retrospectively. Information was collected 
from medical records, patient charts, and the intensive care electronic monitoring 
system IntelliVue Clinical Information Portfolio (ICIP, Philips Medical Systems, 
Eindhoven, the Netherlands). The following parameters were recorded at admission; 
time and date, department affiliation, demographics, comorbidities, vital parameters, 
suspected focus of infection and GCS. During surveillance of patients, variations in 
vital parameters, urine output and biochemical analyses were followed. Timing and 
adequacy of antimicrobial agents was evaluated together with their appropriateness 
according to local recommendations (presented in Paper I). Use of non-invasive or 
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invasive ventilation support and administration of intravenous fluids, vasoactive drugs, 
glucose-insulin and corticosteroids was registered. Simplified Acute Physiology Score 
II (SAPS II) was calculated in patients treated in an ICU bed. Surgical treatment in 
relation to severe infection was documented. Results from blood cultures and 
microbiological analyses of urine, abscesses, sputum, feces, deep tissue samples and 
cerebrospinal fluid were collected. Probable contaminants and commensals were 
excluded from analysis. Antimicrobial susceptibility patterns of cultured pathogens 
were registered when available. Finally, total hospital and ICU length of stay (LOS) as 
well as hospital and 28-day mortality rates were recorded. At discharge a final 
diagnosis was established by one consultant (S. Skrede), based on retrospective 
evaluation of all available records, clinical, microbiological, laboratory and diagnostic 
imaging data. Data from medical records and patient charts was verified before it was 
entered into a local database. The main outcome measure in both paper I and II was 
hospital mortality. Hospital survivors were followed up for 5 years after discharge. 
 
3.2. Summary of Methods Paper ΙΙΙ 
Paper III describes a two year retrospective study from the years 2011 and 2012 
conducted with data from the Norwegian Patient Registry (NPR) and Statistics 
Norway [153, 154]. The NPR is run by the Norwegian Directorate of Health and all 
Norwegian hospitals are obliged to report data from all of their admissions, including 
demographics, dates of hospitalization, characteristics of hospital and department, 
outcome, ICD-10 diagnostic codes as well as codes for surgical and medical 
procedures. First, we performed a primary search for selected discharge codes for 
infection, SIRS and sepsis (Textbox 4). For the eligible cases, up to eight additional 
codes for acute organ dysfunction were then registered. Information about hospital 
stay (days), hospital mortality and demographics for each patient, as well as the total 
number and duration of hospital stays in Norway during the study years was also 
collected from the NPR. Statistics Norway was used to find national population data 
and the national number of hospital deaths. The extracted information was processed 
and made into a local database in the program FileMaker, Inc, Pro (version 14.0; Santa 
Clara, CA, U.S.).  
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Textbox 4. ICD-10 discharge codes applied in paper III 
 
Infection, sepsis or SIRS  
ICD-10 code Diagnosis 
A02.1 Salmonella sepsis 
A20.7 Septicaemic plague 
A21.7 Sepsis (generalized) tularemic 
A22.7 Anthrax sepsis 
A24.1 Acute and fulminating melioidosis 
A26.7 Erysipelothrix sepsis 
A32.7 Listerial sepsis 
A39.2 Acute meningococcaemia 
A40 (.0, 1, 2, 3, 8, 9) Streptococcal sepsis 
A41 (.0, 1, 2, 3, 4, 5, 8, 9) Other sepsis 
A42.7 Actinomycotic sepsis 
A46 Erysipelas 
A48.3 Toxic shock syndrome 
A54.8 Other gonococcal infections 
B37.7 Candidal sepsis 
J09 Influenza due to identified zoonotic or pandemic influenza virus 
J10 Influenza due to identified seasonal influenza virus 
J13 Pneumonia due to Streptococcus pneumoniae 
J14 Pneumonia due to Haemophilus influenzae 
J15 Bacterial pneumonia, not elsewhere classified 
J18 (.0, 1, 2, 8, 9) Pneumonia, unspecified microbiology 
J36 Peritonsillar abscess 
J39 Other diseases of upper respiratory tract 




M72.6 Necrotizing fasciitis 
N10 Acute tubulo-interstitial nephritis 
O85 Puerperal sepsis 
P36 Bacterial sepsis of newborn 
R57.2 Septic shock 
R65 (.0, 1, 9)  
Systemic Inflammatory Response Syndrome [SIRS] of infectious origin 
without (.0) or with organ dysfunction (.1), or not further specified (.9) 
T81.4 Infection following a procedure 
  
  
Organ dysfunctions  
ICD-10 code Diagnosis 
D65 Disseminated intravascular coagulation [defibrination syndrome] 
D69 Purpura and other haemorrhagic conditions 
E87.2 Acidosis 
I50.9 Heart failure, unspecified 
J80 Adult respiratory distress syndrome 
J95 Postprocedural respiratory disorders 
J96.0 Acute respiratory failure 
K72 Hepatic failure 
N17 Acute renal failure 




3.3. Statistical Methods 
Descriptive statistics for continuous variables are presented as mean ± standard 
deviation (SD) or median and interquartile range (IQR), and compared between groups 
with Student’s unpaired t-test when normally distributed and the exact Mann–Whitney 
U test when not normally distributed. Categorical variables are presented as 
frequencies and percentages, and compared between groups with the exact Pearson’s 
chi-squared test (χ2) with odds ratios (ORs) and 95% confidence intervals (CIs). 
Binomial logistic regression analysis was performed to identify predictors of outcome 
in paper I and predictors for ICU-admission in paper II. A multivariable stepwise 
backward model was used to adjust for confounding variables, and identify a final 
simplified model including only predictors significant at the 0.05 level. Results are 
reported as ORs with 95% CIs and p-values from the likelihood ratio (LR) test. 
Variations in effects (ORs) were evaluated to control for influence of collinearity 
among the explanatory variables. Hosmer–Lemeshow’s goodness-of-fit test is reported 
for the fully adjusted and the final models.  
Survival is illustrated with Kaplan-Meier plots, and the log-rank procedure was used to 
test for survival differences within categorical variables. Multivariable survival 
analysis was performed using Cox’s regression model to determine prognostic 
components for long-term mortality in paper II, and results are presented as hazard 
ratios (HRs) with 95% CIs and p-value from the LR test.  
The statistical analyses were performed using IBM SPSS Statistics (Aramonk, NY, 
U.S.). All tests were two-tailed, and a p-value < 0.05 was considered statistically 
significant. 
 
3.4. Calculation of population incidence and all-cause mortality rate 
In paper I, annual population incidence and the 28-day all-cause mortality rate was 
calculated with exclusion of patients transferred from affiliated hospitals, with the 
number of inhabitants > 15 years in the local catchment area in the study year as 
denominator.  
In paper III, annual population incidence was calculated as the total number of 
included patients, with the sum of the total number of inhabitants in Norway during 
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the study period as denominator. In this paper, population incidence by age and gender 
was compared by incidence rate ratios (IRRs) with 95% confidence intervals (CIs). 
The IRRs were computed with MedCalc for Windows (Ostend, Belgium).  
 
3.5. Ethics 
All three studies were approved by the local Regional Ethics Committee (REC West) 
and conducted in accordance with the principles of the Declaration of Helsinki, with a 
waiver of informed consent (case number 2010/165 for paper I and II, and case 
number 2014/1922 for paper III). The prospective study (paper I and II) was initially 
approved as a quality study by the local privacy ombudsman in 2007. An extended 


















4. SUMMARY OF MAIN RESULTS 
4.1 Summary of results - Paper Ι 
In total 220 patients with community acquired severe sepsis were enrolled 
prospectively, yielding an annual incidence of 50 per 100 000 inhabitants. They 
represented 0.34% of the total somatic admissions at Haukeland University Hospital 
during the year 2008. Median age was 67 years, 53% were male and 90% had 
significant comorbidity. The infectious source was correctly established at admission 
in 69% of patients, but the level of precision was highly dependent on the infection 
type and was low in e.g. abdominal infections (50% correctly identified at admission) 
and AIE (33% correct). Overall, 11% had an incorrectly proposed and 16% had an 
unidentified focus, while in the remaining 4% of patients infectious diagnoses were 
not suspected. The most frequent focus of infection, representing 52% of verified 
cases, was the respiratory tract. Genitourinary, abdominal and soft tissue infections 
were each found in 12-14%. The microbiological etiology could be identified in 61% 
and 37% of blood cultures were positive. The microbiological verified infections were 
monomicrobial in 81%.  Overall, Gram-positive microbes represented 57% of 
pathogens. Streptococcus pneumoniae, Escherichia coli and Staphylococcus aureus 
were most prevalent. Troublesome antimicrobial resistance was observed in only two 
isolates containing ESBL-producing Escherichia coli. Median delay before 
administration of the initial dose of antimicrobial therapy was 2.8 hours after hospital 
admission. The delay was highest in abdominal infections (6.9 hours) and in patients ≥ 
75 years when compared to the rest of the cohort. Empirical treatment was also less in 
compliance with current recommendations in the oldest cohort. Further, compliance 
with the recommendations proved to have been better when adequate therapy was 
given, in comparison to when inadequate therapy was given (83% vs. 44%, χ2 P< 
0.001). The hospital case fatality rate (CFR) was 25%. Independent predictors of 
hospital death were abdominal infections, endocarditis, underlying malignancy, 
cardiovascular disease, undefined microbiological aetiology, delayed administration of 
antimicrobial agents ≥ 6 hours and use of inadequate antimicrobial regimens. A 
tendency towards higher hospital mortality with increasing age was observed, but it 
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was not statistically significant. Overall, one-year all-cause mortality was 34.5% and 
four-year mortality was 55.5%. 
 
4.2 Summary of results – Paper ΙΙ 
In this paper, the patients with community acquired sepsis from the prospective study 
were separated according to their highest level of care during hospitalization (ICU 
versus non-ICU level). One hundred and seven patients were included in the ICU 
cohort and 113 in the non-ICU cohort. There were no significant demographic 
differences. Except for dementia, underlying comorbidities were also similarly 
distributed, while do-not-resuscitate orders were more common at ICU-level. 
Respiratory tract infections (RTIs) were the most frequent infection category at both 
care levels. Further, abdominal infections were more often encountered in ICU 
patients (77%, χ2 OR 4.10 (1.58, 10.66), P = 0.003), while most genitourinary 
infections were treated at non-ICU level (81%, χ2 OR 0.21 (0.08, 0.53), P < 0.001). 
Initially, soft tissue infections were also unequally distributed as 24 out of 27 patients 
were referred to non-ICU level. However, subsequent transfer of nine cases to an ICU 
evened this category. ICU patients had a greater burden of multiple organ 
dysfunctions, as 81% had three or more dysfunctional organs compared to 47% of the 
non-ICU cohort. Treatment intensity was consistently higher at ICU level. Supportive 
therapy with vasoactive drugs and non-invasive ventilation was also documented in 
22% and 27% at non-ICU level, however only four patients received both. 
Administration of the initial dose of antimicrobial therapy occurred later at ICU level 
(median 3.5 versus 2.0 hours in non-ICU patients, p = 0.011). Median hospital LOS 
was 15 versus 9 days (P = 0.001), and hospital and 5-year mortality 35% versus 16% 
(P = 0.002) and 57% versus 58% (P = 0.892) in the ICU and non-ICU cohorts, 
respectively. Independent impact on long-term survival was found for increasing age 
(HR 1.06 (1.04, 1.07) per year, P < 0.001), and not care level during hospitalization 




4.3 Summary of results – Paper ΙΙΙ 
A total of 13 582 patients with 18 460 sepsis admissions were identified, of whom 
53.9% were men and mean and median age was 73 and 78 years, respectively. The 
overall annual population incidence was 140 per 100 000 inhabitants, but differed with 
age from 10 to 2 270 patients per 100 000 inhabitants and was significantly higher 
among men in all adult age categories (Figure 4). Sepsis hospitalizations represented 
1.0% of somatic hospital admissions and 3.5% of the total admission days during the 
years 2011 and 2012. Infections of the respiratory tract were most common, occurring 
in 64.2% of cases, and 14.7% had two or more acute organ dysfunctions. Median 
length of stay was 9 days. Hospital mortality for sepsis admissions was 19.4% and 
increased with age and number of organ dysfunctions. During the study period, 26.4% 
of the included patients died while hospitalized for sepsis. Sepsis related deaths 









5.1 Methodological considerations  
5.1.1. Study designs, patient populations and data collection 
The aim of this thesis was to describe sepsis in Norwegian hospitals from both a 
quantitative and qualitative perspective. To accomplish this, a prospective design was 
chosen in the first study (paper I and II), whereas a retrospective, code-based approach 
was used in paper III. 
 
5.1.1.1. Prospective, single-center study of community acquired sepsis 
By this method adult, case-defined patients were enrolled for one year in a single 
hospital.  The study design secured that all patients within the defined population at 
risk were screened for eligibility by a quality-controlled inclusion process. Data were 
collected from all available sources of patient information, with high level of detail, by 
a limited number of study investigators. In this way, the number of missing data was 
minimized. To secure that the results were not influenced by seasonal changes in 
infectious diseases, inclusion lasted an entire year. It has been shown that even case-
defined identification of sepsis may be subject to high variability [130]. However, in 
this study all eligible cases were discussed in consensus meetings within the study 
group before a final decision of inclusion was made. Furthermore, one experienced 
consultant (S. Skrede) reviewed all of the included patients retrospectively after 
discharge to secure diagnosis category, interpretation of microbiological tests, and 
appropriateness of antimicrobial therapy. Screening was in principle performed on 
daily basis.  There were more than 100 different case report form variables registered. 
Yet, from a statistical viewpoint, a relatively small sample size was obtained. We 
chose to exclude patients with nosocomial infections, as these constitute a separate 
entity and hospital-wide inclusion of cases was not feasible within the study resources. 
We would like to have categorized patients with healthcare-associated infections 
separately, e.g. in residents from nursing homes, enabling us to explore unique features 
of this cohort [155]. Although we aimed to investigate community acquired sepsis in a 
hospital-wide setting, we limited inclusion to three departments. This may have led to 
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some missing cases. However, the selection of departments was based on a previous 
unpublished pilot-survey of community acquired sepsis, where we found that a small 
fraction of sepsis patients were treated in other locations at our hospital. The restriction 
of our current study to a single University hospital that holds a referral center function, 
with inclusion of patients from a combined ICU/ non-ICU ward in the non-ICU cohort, 
means that the results not necessarily have external validity in other Norwegian 
hospital settings. Still, we chose to include patients transferred from affiliated hospitals 
to best describe the clinical characteristics of patients with sepsis in a tertiary care 
environment. When calculating population incidence, transferred cases were however 
excluded from analysis. Unfortunately, we were unable to stratify the non-ICU 
patients by severity scoring.  This would have been valuable for comparison with later 
sepsis studies. 
 
5.1.1.2. Retrospective, code-based national sepsis study 
Study III aimed to provide nationwide, quantitative data on sepsis in Norwegian 
hospitals, the former being its main strength. A national prospective multicenter 
survey of such nature, including both community and hospital acquired sepsis cases, 
seemed unfeasible. Thus, a retrospective method was applied. As a national register, 
the NPR holds excellent standard. Every hospital in Norway is obliged to provide data 
from all of their admissions. As NPR does not give access to patient’s health care 
records, the study data are limited to the information specified in the register. To 
increase its robustness, the study period comprised all discharges registered within two 
full calendar years. When the study was conceived, the years 2011 and 2012 were the 
most recent years from which complete NPR data were available, and thus these two 
years were chosen. Identification of sepsis by use of ICD-codes relies not only on 
physicians’ ability to recognize sepsis in their work. It is also dependent on the use and 
quality of diagnostic codes in the patient’s discharge reports. There are no specific 
codes for organ dysfunction caused by infection.  Furthermore, fatalities could in a 
similar manner primarily be the outcome of another co-occurring condition. Overall, 
we have therefore inevitably missed some cases, while others may be false positive.  
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Since one of our aims was to compare data from this study with previous data from 
1999, we selected a spectrum of diagnostic codes as similar as possible to the codes 
applied in the previous Norwegian investigation [67]. However, since specific codes 
for SIRS and sepsis with organ dysfunction now had been introduced, we added these 
together with the code for neonatal sepsis to our primary search.  
Importantly, the reuse of the method from 1999 was also founded in a review of the 
previous literature. Several authors have advised against limiting codes in 
retrospective studies to diagnoses specific for sepsis and septic shock only. Such an 
approach has been found to yield more severely ill patient populations than 
prospective settings, and underestimate sepsis incidence [51, 83, 156]. One study from 
the U.S. came to the opposite conclusion, but that study referred to cohorts with very 
high mortality rates up to 50% [84], indicating too narrow inclusion of cases. Also, 
their selection of infection codes included far more diagnoses than our current study. 
The latter was based on one of the most early and widely cited surveys on sepsis 
epidemiology, performed by Angus and coworkers [77]. Indeed, Angus’ selection of 
codes has been copied by many authors up to date, although this method has not been 
further evaluated since the introduction of sepsis specific codes in 2003. It is thus 
primarily based on codes for various infections (n = 642); including both infections 
that in most circumstances are not severe, and conditions that are rarely the cause of 
sepsis. In comparison, our current study included a total number of 63 ICD-10 codes. 
A comment concerning our selection of codes is that AIE was not included. Three 
factors reduce the influence this might have had on the current results. Firstly, AIE is 
rare, with an estimated population incidence of 3 to 15 cases per 100 000 inhabitants 
per year [157-159]. Many cases do not present with organ dysfunction, e.g. the cases 
with AIE in our prospective study constituted 1 in 3 of all AIE cases admitted to 
Haukeland University Hospital that year (S. Skrede, personal communication). Finally, 
most AIE cases are blood culture positive (≥90%) [159, 160]. A diagnostic code for 
microbial etiology is thus presumably frequently registered in this disease, and 
consequently included in registry data. 
All studies that have evaluated a prospectively registered cohort against cases 
identified retrospectively by coding conclude that the retrospective approach leaves a 
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considerable number of undetected patients [55, 161, 162]. Noticeable, subanalyses in 
a Swedish survey showed that only community acquired sepsis was underestimated; 
nosocomial sepsis was on the contrary overestimated [161]. Nevertheless, an 
investigation that evaluated the Norwegian method from 1999 found that it identified 
only 39% of the sepsis cases in a Swedish prospective ICU-registry [162]. However, 
unlike in our current study, the new sepsis specific codes were not applied in that 
evaluation. There is also a possibility that the Norwegian method was erroneously 
interpreted due to an erratum in the original paper, where diagnoses for pneumonia are 
listed among codes for organ dysfunction instead of among infections. Last, the 
magnitude of the Swedish results is further indefinite as less than half of sepsis 
patients in eligible randomized controlled trials have actually been identified in the 
current ICU-registry [161]. In any case, the Norwegian method was definitely superior 
to two other simultaneously investigated retrospective methods, and overall we found 
it most suitable [76, 77]. 
 
5.1.4. End-points, follow-up periods and estimation of occurrences 
The primary end-point in all of the three articles in this thesis is hospital mortality. In 
paper I and II, this was presented with CFRs as all hospital deaths were reviewed and 
the primary cause verified to be sepsis. We additionally provided 28-day mortality for 
the prospective study, as this parameter often is given in international sepsis literature. 
In the retrospective study only all-cause hospital mortality could be estimated, as this 
is the outcome registered in the NPR. 
The prospective study (paper I and II) also presents long-term mortality for up to five 
years after sepsis hospitalization. Not only was information about mortality beyond 
hospital deaths non-existent in Norway previous to this study, also international data 
were scarce [163-166]. One large study from the United States had surveyed sepsis 
patients for five years after hospitalization, but that was a retrospective survey [166]. 
Assessment of long-term mortality in a prospective cohort was thus an important aim 
of this work. A limitation of our data is that we could not determine the cause of death 
in fatalities occurring after hospital discharge. Neither did we provide comparative 
data from the background population, both of which would be of interest.  
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Annual population incidence of community acquired sepsis as well as total sepsis 
patients in Norwegian hospitals were estimated in this thesis. The denominator in both 
estimates was the total number of inhabitants in the respective background populations 
for the calendar years studied, given by Statistics Norway. To calculate incidence, 
theoretically one should consecutively subtract the number of days left in the 
observation period for patients developing the disease of interest when measuring the 
size of the population at risk, or in the case of community acquired sepsis, even the 
sum of hospitalized days for patients admitted due to other conditions. Because the 
number of cases in our study was so small this would very unlikely have influenced 
our results [55]. Since we also considered nosocomial sepsis in the retrospective 
cohort, the latter was not an issue in that study. 
When estimating the percentage of sepsis hospitalizations among the total number of 
hospitalizations in Norway in paper III, we excluded psychiatric admissions. Other 
researchers have excluded patients of minor age (< 18 years), and some have excluded 
hospitalizations related to childbirth. Since nosocomial sepsis was part of our 
investigation, we found rationale for inclusion of all patients in somatic hospitals. We 
age-stratified annual population incidence, but did not sub-specify the total number of 
hospitalizations according to age categories.  
In the prospective study, we excluded any hospital admission later than the first 
community acquired sepsis episode. However, later we realized that re-hospitalization 
due to new episodes with infection in sepsis survivors is common [167]. By excluding 
these hospitalizations, valuable information about the true impact of sepsis on health 
care is lost. In the retrospective study, we therefore chose to include multiple 
admissions. However, we excluded any admission representing more than a fifth 
sepsis episode in the same individual during the two study years, after a manual review 
of our data had showed some cases with unreasonably many episodes. We suspect that 
these were e.g. patients in permanent renal replacement therapy subject to incorrect 




5.1.5. Definitions of sepsis 
In the prospective study, sepsis was defined according to the contemporary definition 
as infection with fulfillment of two or more SIRS criteria and presence of acute organ 
dysfunction(s). For identification of organ dysfunction, we used the local sepsis 
guideline at Haukeland University Hospital which contains the following minor 
modifications of the second sepsis definition:  
 
• Hypoxemia (SpO2 <90% while breathing air)  
• Acute oliguria (urine output <0.5 ml/kg/h for at least 4 hours)  
• Lactic acidosis (pH <7.30 and s-lactate >4.0 mmol/l)  
• Thrombocytopenia (platelet count <100 x 109/ l or a 50% reduction ≤3 days)  
  
 
Definition of hypoxemia according to SpO2-values instead of PaO2/FiO2 ratio was 
done in order to facilitate diagnosing in a non-ICU environment.  In most cases SaO2-
values from blood gas analysis were considered, as SpO2-measurement can be 
inaccurate. The other modifications are stricter than the original criteria presented by 
Levy and coworkers, which gives the possibility that our prospective sepsis cohort was 
slightly biased towards a more severely ill patient population. This is especially true 
for the parameters oliguria, where we doubled the minimum hours of low urine output, 
to minimize the risk that the cause was simply dehydration, and hyperlactatemia where 
we chose a cut-off of 4.0 instead of the 3.0 mmol/l recommended by the definition at 
that time. We attempted to calculate SOFA scores retrospectively in this cohort, but 
were unable to determine accurate scores for the majority of cases.  We could however 
demonstrate that all of our included patients fulfilled the Sepsis-3 definitions in terms 
of having an increase in SOFA score ≥ two points. This ascertains the present validity 
of our data. 
We chose to refer to the current definition for sepsis (Sepsis-3) at the time of 
publishing paper III. Since the patients included were hospitalized in the years 2011 
and 2012, their diagnoses were not given according to SOFA scores. However, the 
Sepsis-3 definition only recommends, and not requires, that organ dysfunction is based 
on SOFA scoring. Thus we considered the obligate part of the definition, i.e. life-
threatening organ dysfunction caused by a dysregulated host response to infection, 
51 
 
adequately covered by use of diagnostic codes. However, the definition of septic shock 
given in Sepsis-3 differ to such an extent that we are not providing estimates of septic 
shock, only cardiovascular organ dysfunction, in paper III.  
 
5.1.6. Statistical considerations  
To explore if there were independent predictors of hospital mortality and care level 
affiliation in paper I and II, we used a multivariable stepwise backward model to 
adjust for confounding variables. The Hosmer-Lemeshow’s test of goodness-of-fit was 
used to verify the regression models for calibration. Further, the models were checked 
for collinearity by evaluating how the effect (OR) of each variable varied between 
different settings (i.e. between the unadjusted, fully adjusted (multivariable), and the 
final simplified model). In paper I, the variables in the multivariable analyses were 
screened to avoid collinearity by including only those with p < 0.10 in the unadjusted 
analyses (empirical antimicrobial therapy in cases with positive microbiological 
samples were excluded in the reported model due to sample size). In paper II, we had 
pre-specified the explanatory variables based on plausible relationships with the 
dependent variable.  These were included without regards to statistical significance in 
the univariate analyses. Collinearity is especially a problem with regards to the many 
comorbidity variables in both papers. Another possible problem with the many 
comorbidity variables is that we ended up with inclusion of a higher number of 
explanatory variables than recommended to avoid over-fitting in the final model in 
paper I (it is recommended to have at least 10 end-points (e.g. fatalities) per 
explanatory variable, and in this study there were n = 55 deaths). Since no formal 
adjustment for multiple testing was performed, more emphasize should be given to the 
most significant predictors in the final model in paper I (i.e. with p < 0.01). In the 
logistic regression analyses shown in table format in paper I and II, all explanatory 
variables are categorical. In paper I we additionally tested for linear trend in age and 
timing of antimicrobial therapy to best explore the relationship of these categories with 
outcome. As there were two extreme outliers in timing of antimicrobials, we 
performed logarithmic transformation before inclusion of this variable to achieve 
linearity without excluding any cases. 
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Survival analysis was performed by two methods in this thesis: Kaplan-Meier and 
Cox’ regression statistics. The Kaplan-Meier method is a non-parametric test where 
the number of patients at risk influences the accuracy of the survival estimates. Hence 
these are more precise at the start versus towards the end of a study, especially if there 
are a relatively small number of cases, as in our prospective study. An extenuating 
feature of our model is that follow-up was complete for all patients, which means that 
there were no censored cases in the analyses. Kaplan-Meier does not permit 
incorporating continuous explanation variables, and cannot adjust for covariates by 
stepwise addition of several variables. To investigate if there were variables with 
independent effect on long-term survival, a Cox regression analysis was thus applied 
in paper II.  
Several of the significant results from the statistical analyses in the prospective study 
(paper I and II) have relatively wide 95% CIs, as an expression of the small sample 
size in some categories. The magnitude of the effect on the outcome of interest is 
therefore difficult to ascertain. The most extreme example is the category Endocarditis 
in the multivariable analysis in paper I, which has an OR of 18.94 with a 95% CI 
ranging from 3.45 to 104.06 in the final model. Relatedly, in retrospect we see that 
some of the χ2 p-values in the results section in Paper I lack ORs and 95% CIs. 
Besides, the IQRs for the medians in this paper are not specified. 
 
5.2 Discussion of the Results 
5.2.1. Incidence of sepsis in Norway 
In this thesis, the annual population incidence of hospitalized sepsis in Norway was 
estimated to 50 per 100 000 inhabitants when restricted to patients > 15 years of age 
with community acquired infections in the year 2008, and to 140 per 100 000 
inhabitants for all cases in the years 2011 and 2012. The previous estimated overall 
annual population incidence of sepsis in Norway was 50 per 100 000 inhabitants [67]. 
Since we used a similar method as that study from 1999, we find it plausible that the 
observations in paper III reflect that sepsis occurrence is increasing. This is in 
accordance with recent studies and may be attributable to a growing population at 
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elevated risk for infection [74, 76, 77, 79, 85, 93, 110]. Retrospective observations can 
additionally be biased by changes in discharge coding patterns (Figure 2) [129]. By 
including both codes for severe infections, SIRS, sepsis by causative pathogens, and 
septic shock in the primary search, we tried to minimize this problem. Nosocomial 
infections constitute a considerable amount of sepsis cases (33 - 73%) [88, 89, 91, 95, 
96, 99, 101, 113]. The detected incidence in our prospective study is therefore well in 
line with the retrospectively obtained observations.  
Although there are numerous international reports on sepsis epidemiology, population-
level incidences have only been provided in eight countries and solely four previous 
European studies have provided nationwide data [58, 67, 69, 70, 74, 124]. There are 
substantial differences in the previous estimates, which partly can be attributed to 
different study designs (Table 1) [59, 124, 128, 168]. Overall, our current nationwide 
estimate is similar to recent results from two nationwide retrospective European 
surveys (140 and 110 per 100 000 inhabitants per year) as well as a population-based 
investigation from China (190 per 100 000), while the most recent studies from the 
U.S. report higher figures (mostly of the order 300 to 400 per 100 000) [58, 70, 74, 81-
83, 85]. This may be a reflection of different health care systems, but also different 
ICD-coding practices [59]. Medical care in Norway and most of Europe and China is 
government funded, in contrast to the U.S. where it to a greater degree has been 
funded by private insurances. It may therefore be speculated that a large cohort of 
predisposed persons will seek and receive medical care at an earlier stage of an 
infectious episode in Europe and China, before the development of sepsis. The low 
percentage of patients with sepsis (16.0%) in the primary cohort of patients with 
infection in our retrospective report supports this assertion. Moreover, studies from the 
U.S. report incidence as the number of sepsis admissions per unit of population older 
than18 years of age. If we use the same criteria, our corresponding rate is 290 per 100 
000 population in the year 2012 (data not shown). This highlights that awareness of 
methods and criteria for inclusion is crucial in epidemiological sepsis studies. 
Previous population-level prospective investigations with calculations of sepsis 
occurrence are scarce and mostly confined to community acquired cases [55, 117, 121, 
123]. A Spanish study from the year 2003 estimated the annual incidence of 
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hospitalized sepsis to 100 per 100 000 inhabitants >18 years of age, from a cohort 
where 83% of infections were community acquired [117]. Higher figures were 
reported in a one-year prospective survey from the medical ED of a Danish University 
Hospital [55]. They estimated an annual incidence of 457 per 100 000 inhabitants ≥ 15 
years of age during the years 2010 – 2011, corresponding to 13% of all patients 
admitted to the respective ED. Similar high occurrence rates were estimated in a recent 
Swedish study that retrospectively reviewed patients with a new administration of 
intravenous antibiotics during four different days in 2015 [57]. They calculated an 
annual incidence of 687 and 780 per 100 000 inhabitants with the Sepsis-2 and Sepsis-
3 definition respectively. Both our prospective and retrospective survey identified a 
considerably lower incidence than these recent Scandinavian reports. Regarding our 
prospective study we may have missed some patients by not screening all ED 
admissions, but we believe the difference is also explained by dissimilar inclusion 
criteria. Whereas we used strict definitions for organ dysfunction, the Danish study 
defined respiratory dysfunction as oxygen saturation by pulse oximetry < 92% at 
arrival or arterial oxygen tension < 9.75 kPa, in a cohort where 68% of cases presented 
with RTI. Respiratory organ dysfunction was present in 65% of their subjects, while 
cardiovascular and renal dysfunction was present in only 7% and 9% respectively. 
When we evaluated patients with RTI for eligibility in our prospective study, strict 
clinical judgement was used for patients with e.g. pre-existing COPD. In the 
retrospective study such evaluation was not possible, but we tried to overcome this 
problem by excluding codes for infectious exacerbation of COPD. Indeed, the focus of 
the studies in this thesis has been to identify patients that to the most certain degree 
have organ dysfunction caused by a dysregulated inflammatory response to infection. 
We speculate that some studies have mainly focused on identifying patients with 
infection fulfilling the criteria for organ dysfunction, without further regard to the 
mechanism eliciting this dysfunction. In our retrospective survey we found that sepsis 
cases constituted 16% of patients with confirmed infection. This is comparable to 
recent results from China, but only half of what was found in the respective 
Scandinavian studies. Interestingly, the estimated annual incidence of sepsis in the 
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Chinese study (190 per 100 000 population ≥ 18 years) is also comparable to our 
results.   
The two other Scandinavian studies have investigated how many of their sepsis 
patients that were retrieved by use of ICD discharge codes. Both found a low detection 
rate, close to 15%. It would have been interesting to know how many of the patients in 
these studies that were assigned a code for related conditions, such as exacerbation of 
COPD or pyelonephritis with prerenal and shortly resolving oliguria. In the end, as 
long as sepsis is case-defined, comparisons between studies will not only be 
influenced by the choice of methodology, but also hampered by the subjective 
component in the perception of the syndrome [130].  
 
5.2.2. Utilization of Norwegian hospital capacity and ICU resources  
In the year 2008, we estimated that community acquired sepsis in adults caused 0.34% 
of the total somatic admissions (n = 64 405) at Haukeland University Hospital (P. O. 
Vadset, hospital data management unit, personal communication). During 2011 and 
2012 the corresponding admission rate was 1.0% for all patients hospitalized with 
sepsis, a considerable increase from the previous Norwegian estimate of 0.3% from 
1999. Other international studies present admission rates in the range of 0.9 – 2.3% 
[58, 70, 74, 75, 77, 82, 117, 123]. The highest rate was found in the retrospective U.S. 
investigation which included a great number of codes for infection [77], while studies 
that included all age categories in their analyses are on the opposite end of the scale 
[70, 74]. There are little data on which fraction patients with community acquired 
sepsis constitute of total hospitalizations, and most studies are restricted to ED 
admissions [55, 78, 116, 169]. Only two prospective studies, from Spain and Northern 
Australia respectively, have calculated rates from all hospitalized patients. Both 
estimates are considerably higher than our 0.34%, around 1.5% each [117, 123]. It is 
however unclear how comprehensive the account of total somatic admissions was in 
these studies. In addition to including e.g. the Department of obstetrics and 
gynecology as a somatic unit in their hospital management statistics, Haukeland 
University Hospital serves as a referral center and has comprehensive activity on a 
regional and national basis in several fields, possibly influencing our results.  
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The total utilization of hospital days for sepsis patients during 2011 and 2012 equaled 
3.5% of all somatic overnight stays in Norwegian hospitals. The mean and median 
LOS was fourteen and nine days, which is comparable to several contemporary results 
[75, 81, 85], yet lower than other findings [58, 74].  In 2008, the median LOS for 
community acquired sepsis at Haukeland University Hospital was eleven days. This is 
higher than the eight days reported by the simultaneously performed study from 
Northern Australia and definitely higher than the six days found in a U.S. retrospective 
study comparing the characteristics between community acquired and nosocomial 
sepsis [123, 170]. This supports an assumption that patients in our prospective study 
were more severely ill than those of other cohorts with inclusion of non-ICU treated 
patients. The median ICU LOS was also shorter in the two before mentioned studies, 
four and three days respectively, versus six days in our patients. However, other 
observations include both shorter and longer median ICU stays, leaving our findings 
well within the range of previous results [44, 91, 95, 117]. Besides, several factors 
such as the threshold for ICU admissions, ICU capacity, and characteristics of the 
underlying infections may bias ICU LOS. Relatedly, sepsis patients have been found 
to account for 10 to 25% of all ICU admissions in various settings [77, 91, 94, 108, 
111, 113, 123]. In 2008, community acquired sepsis constituted 11% of all admissions 
to the general ICU at Haukeland University Hospital (n=423 admissions in 390 
patients). 
The proportion of patients with sepsis treated inside an ICU in our prospective study 
was 49%. Similar ICU treatment rates (32-55%) have been estimated in both 
prospective and retrospective settings [58, 68, 77, 86, 91, 116, 117, 123, 149, 171]. 
Oppositely, in the Danish investigation of community acquired sepsis, only 7% of 
patients were admitted to an ICU [115]. Although the Danish registration was 
restricted to the first 24 hours after hospitalization, it has been shown that most ICU 
admissions for sepsis take place early in the disease course, indicating that their total 
ICU treatment rate would not have changed noteworthy with a longer follow-up period 
[44].  Relatedly, in our study 17% of patients initially admitted to a medical ward were 





5.2.3. Characteristics of Norwegian sepsis patients 
The demographic characteristics of the two sepsis cohorts in this thesis are comparable 
with most cohorts from contemporary sepsis studies (Table 1). Several studies  have 
shown that the mean age of sepsis patients has increased significantly over the past 
decades [74, 76, 93]. Mean age was 58 years in the Norwegian sepsis report from 
1999,  in our prospective study it was 64, whereas in the most recent retrospective 
study it was 72 years [67]. This is likely a reflection of the steadily growing population 
of elderly in our society, and gives reason to assume that the observed increase in 
sepsis incidence will maintain in the forthcoming years. 
A gender related age-specific difference in sepsis incidence similar to that found in our 
retrospective study has been shown previously [58, 70, 75-77]. It has been discussed 
whether observed gender disparities in sepsis occurrence reflect true conditions or 
rather is a bias from different care providing among the sexes [172]. Since we have 
estimated the incidence of sepsis with both hospital and nationwide data, we find 
reason to discard the last objection. The higher occurrence of sepsis among men is 
multifactorial, where chronic health and behavioral factors, gender specific 
susceptibility to microbes, hormones, and genetic factors interacting with immunity all 
may play a part [59, 173]. This topic is however beyond the scope of this thesis.  
Unfortunately, we were unable to adjust for comorbidity when analyzing data in the 
retrospective study. In the prospective study, 90% of the included patients had at least 
one coexisting chronic disease, which is a high percentage compared to previous 
estimates [58, 74, 77, 88, 89, 93, 94, 96, 99, 110, 133, 135]. This may in part be 
explained by our inclusion of hypertension and psychiatric disease categories, 
common conditions that are often not accounted for. Further, cardiovascular diseases 
were the most prevalent category among our patients (49%). Most studies have only 
included coronary artery disease, in some instances restricted to confirmed heart 
attacks [74, 75]. Last, prospective inclusion is the most suitable way of registering 
comorbidity, which means that comparison with retrospective code-based studies in 
terms of absolute proportions is difficult. Nevertheless, our distribution of diagnoses 
from the more to the less prevalent conditions resembles previous studies in general.  
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Studies investigating differences in burden of underlying disease among sepsis patients 
hospitalized inside versus outside ICUs have divergent findings. One prospective 
study found patients on the wards to have more severe comorbidities in terms of a 
worse McCabe score [117], while a retrospective U.S. study found slightly fewer 
comorbidities in this subgroup [122]. Among our prospective cohort, we found that 
dementia was the single unevenly distributed condition with a significantly higher 
occurrence in the non-ICU cohort. Further, a do-not-resuscitate (DNR) order was 
given more frequently in our non-ICU patients (9% versus 5% of ICU patients), but 
the significance disappeared in multivariable analyses. Relatedly, among non-
survivors of the Spanish study, it was a higher proportion of DNR orders in non-ICU 
patients (46% versus 8% in the ICU-patients), but overall, withholding or withdrawal 
of treatment was equally frequent among the different care levels [117]. Differently, 
the retrospective U.S. study found that ICU admitted patients were given slightly more 
DNR orders after examination in the ED (5% vs 4%) [122]. Again, we speculate that 
differences in health care organization may influence the characteristics of patients 
admitted to the different levels of care among different countries. Based on clinical 
experience, we find the results from our prospective study consistent with 
Scandinavian conditions, in line with a retrospective Danish study of community 
acquired sepsis that found that 17% of their patients were not ICU eligible on the basis 
of pre-existing conditions [68]. 
 
5.2.4. Infectious foci and diagnostic precision 
The most common focus of infection in both of the studies in this thesis was found to 
be the respiratory tract, consistent with previous literature (Table 2). In our prospective 
study, the various community acquired infections was differently distributed between 
the care levels (paper II). More specifically, genitourinary infections and abdominal 
infections was the second most frequent focus in the non-ICU and ICU cohort 
respectively. Overall, the total proportion of cases with abdominal infections was in 
the lower range of previous results. Genitourinary infections have indeed been 
reported as more prevalent in studies covering non-ICU patients while abdominal 
infections are more common in explicit ICU settings (Table 2). A distinct finding of 
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our study is that AIE was more prevalent compared to other investigations. Together 
with an increasing occurrence of patients hospitalized due to AIE in general (S. Jordal, 
M.D., personal communication), the tertiary care and referral center status of 
Haukeland University Hospital have influenced this result as 8 out of 12 of our cases 
with AIE were transfers from affiliated hospitals.  
Identifying the source of infection in sepsis by use of discharge codes has important 
limitations, as previously explained. Nevertheless, we chose to specify the proportion 
with the most common infections in paper III and found that RTI was identified very 
often (64%), whereas the three second most prevalent foci showed low frequencies 
(from 4.3 to 4.9% of the cases). In the prospective study, the proportion of cases with 
identified microbiological etiology was lower in RTI compared with other infection 
categories, in line with other prospective investigations of community acquired 
pneumonia [174]. Thus, it is likely a higher probability of receiving one of the 
microbiological founded sepsis codes in other infection categories than RTI. This 
difference may decline if more comprehensive molecular methods become a part of 
routine testing [175, 176].  
An important secondary objective of our prospective study was to evaluate the 
precision of diagnostic practice in sepsis. To accomplish this, we compared the 
confirmed focus of infection at hospital discharge with the suspected focus at 
admission (paper I). We have not found other similar investigations, but it has in a 
related manner been reported that a significant proportion of patients with suspected 
sepsis in fact have noninfectious, mimicking diagnoses [169]. In some infection 
categories our results were worrisome, considering that empirical treatment is tailored 
on the basis of a suspected infectious source. As long as diagnostic algorithms for 
sepsis focus on the identification of an infection’s complications rather than its origin, 
our results justify increased focus on this aspect in everyday clinical practice and 
education. 
 
5.2.5. Microbiological etiology of sepsis in Norway 
In our investigation of community acquired sepsis we identified a plausible pathogen 
in 61% of the microbiological tested patients, and 37% of blood cultures were positive 
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(paper I). These results resemble prospective studies of sepsis from ICU settings [88, 
91, 95, 96, 99, 101, 108, 113, 114, 139, 171]. Other prospective studies with inclusion 
of non-ICU patients present lower detection rates than we found. The Spanish and 
Northern Australian studies included patients with no organ dysfunction and found 
overall rates of 42-45% [117, 123]. Unlike the Spanish results, we did not find a 
difference in the microbiological detection rate between the levels of care (paper II) 
[117]. However, in addition to include patients without organ dysfunction that study 
also comprised nosocomial sepsis, both of which exert influence on the detection rate 
[55, 113, 114, 119, 141]. The studies from Denmark and Sweden that calculated very 
high incidences of sepsis, found growth in blood cultures in solely 13% and 19-24% 
respectively [55, 57]. Overall detection rates are not offered. In retrospective surveys, 
the overall detection rate has been specified at 10% and 26% in two studies [74, 133]. 
Surprisingly, older investigations that included cases without organ dysfunction found 
higher rates, 30 and 51% of patients [67, 76]. All of these rates are however naturally 
dependent on the selection of codes used. We chose not to explore this subject in our 
retrospective study (paper III).  
Gram-positive bacteria were the most common cause of community acquired sepsis in 
our prospective study, representing 57% of all identified pathogens, while Gram-
negative microbes constituted 38% (paper I). A similar distribution was also found 
among positive blood cultures. The overweight of Gram-positive bacteria in our 
environment is different from results seen in many other Western countries at the same 
time. For example, a very large point-prevalence survey of infections in ICUs with 75 
participating countries found Gram-negative bacteria in 62% of patients, Gram-
positive in 47%, and fungi in 19% [140]. In a more recent Norwegian investigation of 
bloodstream infections, Gram-negative microbes similarly constituted 56%, Gram-
positive 38%, whereas 7% of infections were mixed [144]. Compared to a previous 
Norwegian study of BSIs which found Gram-positive aerobic bacteria in 50% and 
Gram-negative aerobic bacteria in 43% of cases during the late 1980s [177], the recent 
Norwegian study shows a change towards Gram-negative bacteria that is more in line 
with international studies than our data. Our study may have been influenced by the 
fact that Gram-negative bacteria have been found more frequently in nosocomial than 
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community acquired infections [113]. Furthermore, an outstanding feature of our study 
is that Streptococcus pneumoniae, which is very uncommon in hospital-acquired 
infections, was the most prevalent microbial etiology [178, 179]. A conjugated vaccine 
was included in the official program for vaccination of children in 2006. From that 
point, a marked decline in cases with invasive Streptococcus pneumoniae has been 
seen, in particular among the elderly [147, 179, 180].  
There are very few studies that specify the whole spectrum of encountered microbes in 
sepsis, and none from settings comparable to our investigation. On the other hand, 
several other Scandinavian studies present results from blood cultures. With exception 
of Staphylococcus aureus being more common than Streptococcus pneumoniae, their 
findings resemble ours [55, 57, 68, 89].  
More than one pathogen was present in 19% of our test-positive patients (paper I). In 
other studies the exact amount of polymicrobial infections is most often not stated, but 
it has been specified between 18 and 36% in explicit ICU sepsis studies during the 
preceding years of our study [101, 108, 114]. Fungal infections were among the 
polymicrobial cases, and altogether eight fungi were detected from a total of four 
patients, indicating that this type of pathogen was more seldom in our hospital than 
other settings at that time [74, 101, 113, 114, 133, 140]. Furthermore, we did not see 
acquired drug-resistance among other microbes than Escherichia coli, of which two 
out of 27 isolates (7%) were ESBL producing. Only one other Scandinavian sepsis 
study, a Swedish survey of 101 patients in a single ICU, have stated that they 
encountered drug-resistant bacteria [89]. Among their blood cultures, two out of 18 
Escherichia coli were ESBL producing (11%). These sample sizes are small, but 
theoretically troublesome resistance could be more prevalent in sepsis than in general 
infections. This could be due to a higher prevalence of these microbes in subjects with 
increased risk of sepsis. In comparison, the Norwegian study of BSIs in a local 
hospital performed during the years 2002 to 2013 found ESBL production in 2% of 
Escherichia coli [179]. The official Norwegian surveillance program for antimicrobial 
resistance (NORM) similarly calculated that 1.5% of Escherichia coli in investigated 
blood cultures were ESBL producing in the year 2008 [181]. Furthermore, this 
proportion increased to 6.5% in 2015, while aminoglycoside resistance simultaneously 
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increased from 2.7 to 6.4% [182]. Thus, the occurrence of multi-drug resistant 
Enterobacteriaceae in Norwegian sepsis cases has increased significantly since our 
study was conducted. Regarding other mechanisms for acquired drug-resistance, the 
Norwegian study of BSIs until the year 2014 encountered only one Methicillin 
Resistant Staphylococcus aureus (MRSA), and 1% of Streptococcus pneumoniae were 
resistant to penicillin [179]. Surveillance of resistance in sepsis patients should be a 
prioritized field to investigate in the future to continuously guide evidence based 
selection of empirical antimicrobial treatment regimens. 
 
5.2.6. Organ dysfunction 
In our prospective study, 88% of patients had more than one dysfunctional organ 
system. This is a higher fraction than in comparable prospective studies. We collected 
data throughout the entire hospital stay for all patients, to ensure an inclusion of all 
cases with organ dysfunction. In fact, two retrospective studies that also performed 
manual reviews of their patient’s medical records found similar figures (77-82%) [68, 
136]. The presence of multiple organ dysfunctions was high also among our non-ICU 
patients, affecting 81% of cases versus 94% of the ICU patients. Nevertheless, the ICU 
cohort had a significantly greater burden with more cases in the range above two 
dysfunctions, similar to other comparable settings [86, 117]. A limitation of the 
comparison between the two levels of care in our study is that we were unable to 
perform severity scoring of all patients. This would have given a more detailed picture 
of the degree of organ dysfunctions. E.g. cardiovascular dysfunction was present in 
68% and 79% of the non-ICU and ICU cohort respectively; however, vasoactive drugs 
were administered in 32% and 94% of the respective patients, indicating that ICU 
patients were more severely affected. Similar to a retrospective Australian sepsis 
investigation, we noticed that cardiovascular, renal, hematological and hepatic 
dysfunction were treated in an ICU in just above half of the cases, while metabolic 
acidosis was most often ICU-admitted (73%) in contrast to neurologic impairment that 
was less often allocated to an ICU (37%) [86]. The Australian distribution of 
respiratory dysfunction (ICU-treated in 89%) is however considerably different from 
our corresponding proportion (56%). The Australian study was performed around the 
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millennium, when treatment facilities outside ICUs probably were less comprehensive 
than at the time of our study some years later. If we transfer non-ICU cases receiving 
ventilation support to the ICU group for comparison, our corresponding estimate is 
80%. Metabolic acidosis was the organ dysfunction with the second highest ICU-
admission rate in both the Australian and our study (73% and 75% of patients). Thus, 
it seems that respiratory and metabolic dysfunctions are especially associated with 
high demands for critical care. Overall, our findings are likely affected by the 
expanded facilities for patient surveillance and treatment that are available outside the 
ICUs in our hospital. This is in particular relevant for the burden of respiratory and 
cardiovascular dysfunctions. In other settings, some of our non-ICU patients may 
therefore have been admitted to an ICU. Apart from hematologic dysfunction, our 
overall distribution of organ dysfunctions is comparable to previous results, with two 
important exceptions that have already been addressed in this thesis [55, 75]. When we 
classified organ dysfunctions, only patients with a diagnosis of DIC and/or purpura 
were included in the hematologic category. This should have been noted in our 
manuscript. If we, like others, had used a definition identical to our inclusion criteria 
(i.e. platelet count <100 x 109/ l), this rate would be comparable (17%, data not 
shown). 
In our retrospective study (paper III), the estimated occurrence of organ dysfunctions 
was much lower than in our prospective study, with multiple dysfunctions present in 
15% of cases. Since the prospective study was performed at a single university 
hospital which serves as a referral center, it is plausible that the overall severity of 
sepsis in that study is above the national average. Also, the retrospective study did not 
include dysfunction of the central nervous system, present in 34% of the prospective 
cases, as we could not find a distinct ICD-10 code to substitute this condition. 
However, these matters probably contributed to a smaller part of the discrepancy, 
while insufficiencies in ICD-coding practice likely caused the greater part. This is 
illustrated by the fact that solely 96 cases (0.5%) in the retrospective study were found 
to have four or more organ dysfunctions during the two study years all together, while 
the corresponding number for community acquired cases in the prospective, single 




5.2.7. Treatment and compliance with guidelines for sepsis management 
Protocolized identification and care for sepsis patients have been the recommended 
norm for one and a half decade, and favorable evidence continues to emerge [46, 138, 
144, 149, 183-185]. Haukeland University Hospital was the first Norwegian hospital to 
establish a hospital wide sepsis guideline in the year 2002, and this guideline has later 
served as a template for many other hospitals. A secondary objective of the 
prospective study was to investigate the nature of sepsis treatment at our hospital and 
to evaluate if this was in accordance with the local guidelines. We chose to focus on 
the use of antimicrobials alone in the evaluation because this is the only parameter that 
is standard for all sepsis patients (paper I). Other therapies were solely compared 
between the two levels of care (paper II). We have not found other studies providing 
details on the treatment of sepsis outside of ICUs. In fact, in a review of evidence 
supporting the use of the 2012 SSC recommendations in patients on hospital wards, 
the authors found that quick administration of empirical antimicrobial therapy was the 
only one of 25 relevant recommendations actually supported by studies that included 
non-ICU patients [186].  
Considering the use of antimicrobial therapy in our study, the local guidelines were not 
followed in approximately one in five patients and the compliance was poorest among 
patients ≥ 75 years of age (paper I). Importantly, when microbe identity and/or 
susceptibility tests revealed that adequate therapy had been provided, compliance with 
routines had been better than when inadequate regimens had been given. This adds 
evidence based rationale for the use of guidelines. 
Overall, the median time from the moment of hospital admittance to administration of 
the first dose of antimicrobial treatment was 2.8 hours in our cohort. Compared to the 
SSC guideline, which since the year 2008 has recommended antimicrobial 
administration to take place within one hour, our result stands out as unsatisfactory. 
Nevertheless, similar results were encountered around the time of our study 
conduction [116, 187], and our results were superior from a previous North-American 
investigation [43]. A further extenuating circumstance is that the last mentioned 
retrospective study of patients with septic shock was the only study accentuating 
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timing of antibiotics available to the SSC guideline from 2008. Last, the SSC uses the 
moment of sepsis recognition while we used admission to hospital as index time [188]. 
Of concern is however the range in our results, with extended delay in abdominal 
infections, elderly patients, and in the ICU cohort compared to the non-ICU cohort. 
Indeed, the majority of abdominal infections did require intensive care, so a higher 
occurrence of abdominal infections may account for some of the delay in the latter 
group or vice versa. In addition, there was a trend towards more preliminary diagnoses 
with an incorrect focus of infection (p=0.123) and also more cases where infection was 
not suspected at all (p=0.094) in the ICU cohort. Altogether, this indicates that a more 
severe and complex spectrum of symptoms necessitated immediate efforts on 
investigative modalities and organ supportive therapeutic measures. Similar 
considerations could be done among the elderly, where more comorbidities including 
higher occurrence of cognitive impairment, as well as greater impairment of renal 
function, was present.  
 
5.2.8. Outcome of hospitalized sepsis patients in Norway 
5.2.8.1. Hospital mortality 
We found that CFR from sepsis was 25% for community acquired cases at a tertiary 
care level in the year 2008, and 19% for all cases nationally during 2011 and 2012. 
These results are well in line with previous international figures [75, 85]. The hospital 
CFR among our retrospective cohort represents a considerable decrease compared to 
the previous Norwegian estimate from 1999 (27%) [67]. Furthermore, during these 
years (1999 to 2011-2012) the mean number of admission days fell and the mean age 
of the patients rose. Similar observations have been made in other international 
nationwide settings [74, 81, 82, 85]. It has been speculated that the recent decrease in 
hospital mortality from sepsis originate from changing coding practices [84, 129]. A 
retrospective study reported that the average number of organ dysfunctions among 
their sepsis cases increased, whereas hospital mortality and mean hospital cost in 
parallel declined [82]. Nevertheless, general improvement in care may still be a major 
underlying cause of favorable trends regarding outcome. In support of the latter is a 
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meta-analysis from the U.S. which concluded that mortality among patients enrolled in 
the control groups of 36 multicenter clinical trials have decreased in a corresponding 
manner as data derived from administrative coding [148]. Further, two major 
nationwide ICU studies have come to the same conclusion [94, 110]. Ideally, future 
code-based epidemiological studies of sepsis should in their search for time-related 
changes specify sepsis mortality at the level of different ICD-diagnoses, and also 
investigate the frequency and mortality of the corresponding cases without organ 
dysfunction(s).  
An additional possible confounder in the measurement of hospital mortality is the time 
to hospital discharge. A shift towards an earlier discharge practice, in our setting 
presumably to a facility in the primary health care services, may transfer late occurring 
deaths from before to after hospital discharge. Interestingly, a national reform issued 
by the Ministry of Health and Care Services in Norway called Samhandlingsreformen 
(English: the Coordination reform), aiming to promote the use of primary health care 
services in order for care providing to occur closer to the patient’s home, was 
implemented January the 1st 2012. In parallel hospital mortality from sepsis decreased 
from 22% in 2011 to 17% in 2012 (paper III). Similarly, hospital LOS for patients 
discharged to a primary care facility (e.g. nursing home) in general decreased with two 
days during the following years [189]. 
Results in our prospective investigation are likely affected by the study center being a 
tertiary care referral center. This makes it difficult to compare mortality among this 
cohort with the previous Norwegian study. Other prospective studies of community 
acquired sepsis have described that 19%, 17% and 28% of their sepsis patients from 
Denmark, Northern Australia and Spain were hospital non-survivors during the years 
2010-2011, 2007-2008 and 2003 respectively [115, 117, 123]. None of these estimates 
are far from our result, even though there are notable variations in study settings. 
Dichotomization of our cohort dependent on the level of care showed that ICU-
patients had more than twofold the mortality as non-ICU treated subjects (35% versus 
16%, paper II). While our hospital mortality at ICU level is similar to many other ICU 
settings (Table 1), mortality in sepsis patients not admitted to an ICU bed was lower 
than in other publications (23-30%) [77, 116, 117, 190]. This discrepancy may be 
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explained by our exclusion of nosocomial infections [191], the year of study 
conduction, as well as our study setting, which may favorably have influenced 
outcome due to qualifications and relative number of the personnel. 
In paper I, we explored predictors for hospital death in community acquired sepsis. 
Increased risk of mortality was found for abdominal infections and AIE using RTI as a 
reference. Abdominal infections are often polymicrobial and anaerobic bacteria are not 
uncommon in this category, meaning there is a significant risk for empirical antibiotics 
to be inadequate in this category when the diagnosis is not suspected at admission 
[192]. All twelve cases with AIE in our study were on the other hand monobacillary. 
Our findings are nevertheless supported by a large-scale national ICU study from 
England, that found AIE to be the infection category with the highest hospital 
mortality in sepsis [94]. We have not found similar adjusted calculations of focus-
dependent risk of mortality from sepsis in other prospective studies with inclusion of 
non-ICU treated patients. ICU-based studies are not consistent in this matter [192], 
with the exception that GUIs are almost invariably reported to have a higher survival 
rate than other infections [77, 94, 95, 110, 193, 194]. A large French ICU study has 
elucidated a possible explanation for the divergent results among previous ICU studies 
[191]. They found no association between site of infection and mortality in a large 
series of sepsis in a 10 year prospective observational cohort. Similar conclusions were 
also drawn for detection of microbiological etiology and mortality. The researchers 
adjusted for both severity of illness and organ dysfunctions (SAPS II and SOFA 
score), in addition to appropriateness of initial antimicrobials which was confirmed to 
be the only independent predictor of outcome. The remaining question is whether or 
not it is correct to consider severity stratification in this matter. The French study 
indicates that there is no explicit impact on survival when the various infections and/or 
pathogens reach the same level of severity. However, overlooking the fact that there 
are dissimilar risks of both sepsis development and sepsis severity among different 
infections seems in our opinion to be of limited clinical value.  
A more uniform finding in sepsis studies is that the timing of initial antimicrobial 
therapy matters [46]. We found that a delay of ≥ 6 hours was associated with an 
increased mortality rate. A high-publicity North-American study have described that 
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each hour of delayed administration of antibiotics from the first hour after septic shock 
recognition was associated with a continuous decrease in survival [43]. Like us, 
several subsequent studies failed to produce similar conclusions [42, 195, 196], but 
corresponding findings have now been produced in three large retrospective analyses 
and thus strengthened the recommended urgency in antimicrobial administration 
substantially [41, 138, 197]. Further restricted analyses presented in our original 
publication (paper I) produced a small but significant impact in multivariable statistics 
of hourly delays on hospital mortality also with our data. In brief, variables such as a 
small sample size, the heterogeneity of the population studied, accounting for 
antimicrobial susceptibility or not, and different definition of index time points are 
likely biases in this question [46]. 
We also found that use of antibiotics prior to hospitalization had a negative relation to 
survival. Two other studies have concluded that antibiotic therapy within the last 30 
days before sepsis admission was independently associated with administration of 
inadequate agents [198, 199]. One of these studies also calculated that to prevent a 
single fatality from sepsis, the number needed to treat with adequate antimicrobial 
therapy was solely four cases [199]. Further, inadequate regimens were associated not 
only with excess mortality but also increased ICU and hospital LOS in survivors in 
another study [200]. Thus, although the sample size in our study was small, our result 
is probably credible.  
Two final independent predictors for hospital mortality in our prospective study were 
severe underlying illness in the form of malignancy and cardiovascular disease. Most 
cancer types have both a higher risk of and increased mortality from sepsis compared 
to non-cancer patients [201]. We have not found specific investigations on sepsis 
patients with pre-existing cardiovascular disease. However, there are currently focus 
on cardiovascular events in sepsis survivors, which comes up as one of the major 
reasons for their increased long-term risk of death [202-204].  
In the prospective study, we observed that an increase in age had a tendency towards a 
parallel increase in hospital mortality in univariable analysis (paper I), but it was not 
statistically significant like in other settings [205]. This could be due to a relatively 
small sample size. Patients ≥ 75 years of age had a significant higher burden of 
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cognitive impairment, on average one extra comorbidity and their creatinine level was 
significantly higher at admission than in younger patients (data not shown). It should 
however be kept in mind that administration of antimicrobial therapy was significantly 
more delayed in this subgroup. Thus, we find reason to question whether previous 
results are explained by host factors alone. Like in other similar settings, hospital 
mortality increased with age in the retrospective study (paper III) without controlling 
for confounding factors [58, 70, 77]. Furthermore, we did not find any significant 
gender disparities in this thesis, neither in hospital (paper I and III) nor long-term 
survival (paper II). Previous large epidemiologic studies have been disparate in this 
matter, making it difficult to draw any conclusions based on our results alone [132, 
206-208]. 
To estimate the impact sepsis has on all-cause mortality, several studies have analyzed 
data from multiple causes of death registries [209-212].This approach is well-known to 
underestimate sepsis-related mortality in comparison to administrative datasets [213]. 
In the retrospective study (paper III) we calculated that sepsis contributed to 1 in every 
8 hospital deaths during 2011 and 2012. In contrast, The Norwegian Cause of Death 
Registry only superficially describes sepsis as a cause of death in their annual report 
[214]. Likewise, a corresponding report from the U.S. specifies that sepsis caused 
1.5% of total deaths in 2014, while two U.S. retrospective code-based investigations of 
hospital mortality have reported that sepsis contributed to 1 in every 2 to 3 deaths and 
18.5% of national hospital deaths respectively, the latter restricted to first-listed 
diagnoses [215-217]. All of the U.S. estimates adhered to the previous definition of 
sepsis and included cases with no evidence of organ dysfunction. However, the 
proportion of fatalities among our primary search (i.e. selection of sepsis, infection, or 
SIRS codes), 29.5% (data not shown), is comparable to the similarly conducted U.S. 
study [216]. Unfortunately we were only able to estimate sepsis’ influence on total 
hospital deaths and not its contribution to population-level mortality in Norway, 




5.2.8.2. Long-term survival after hospitalization for sepsis in Norway 
Long-term survival was described in our prospective cohort only and therefore limited 
to community-acquired sepsis (paper I and II).  All-cause mortality was 34.5% after 
one and 58% after five years. Out of hospital survival was independently affected by 
age but not by care level during index hospitalization, yet the non-ICU treated hospital 
survivors experienced two-fold the mortality as ICU treated subjects after hospital 
discharge. Our results are limited due to a small sample size, however, numerous 
studies have encountered resembling patterns of outcome in sepsis survivors [151]. It 
has long been known that these survivors have a long-lasting increased risk of 
mortality compared to the general population or cohorts of patients hospitalized for 
other conditions [152, 164]. This has also been studied explicitly for community 
acquired sepsis [68, 115, 218], but the most comprehensive investigation were 
performed with inclusion of cases without organ failure [218].  Nevertheless, it has 
only recently been established  that these observed poor outcomes are truly influenced 
by the sepsis episode, rather than pre-existing factors such as comorbidities or hospital 
admittance in general (i.e. similar events would have occurred if the patients were 
hospitalized for another reason) [219]. Such knowledge is of importance should 
targeted interventions to reduce the excess mortality be invented. Two studies, one 
based on a longitudinal prospective cohort in the U.S. and one retrospective 
nationwide survey from Taiwan, have strengthened the evidence for a causal linkage 
to sepsis itself by use of propensity score matching to adjust for possible confounding 
variables [66, 203]. Both studies performed comparison with matched controls from 
the general population as well as patients hospitalized without sepsis, and their 
findings were confirmed up to five years after hospital discharge. A prospective 
Canadian study that focused on previously healthy subjects with ICU admittance for 
sepsis also came to similar conclusions with an average follow-up of ten years [152]. 
Further extenuating the severity of the latter observations is that the excess mortality in 
sepsis survivors was greatest in the youngest subgroup (patients < 60 years of age).  
Analogue to their high long-term mortality, sepsis survivors are invariably found to 
carry more comorbidity than controls. They have a higher occurrence of 
cardiovascular events [202-204], cognitive impairment and functional disability [150], 
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and approximately 60% experience a new hospitalization during the first year after 
sepsis discharge, most often due to infection [167]. The underlying biological 
mechanisms for the increased morbidity and accelerated mortality are currently not 
established. Studies imply that epigenetic regulation is a mechanism of 
immunosuppression in sepsis survivors [220, 221]. Epigenetic alterations could be a 
part of accelerated aging, postulated as a potential mechanism for impaired immune 
function, development of chronic illness and general frailty in these patients. Also, 
exposure to antimicrobials and critical illness may damage the gastrointestinal 
microbial flora and constitute a pathway for secondary infections and rehospitalization 
in addition to immunosuppression [222]. Last, cognitive impairment has been 
suggested to be second to persistent neuronal inflammation affecting the central 
nervous system, or simply originate from degeneration of neurons induced by sepsis-





















6. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
This thesis confirms that sepsis is frequent in Norway, with afflicted cases occupying 
as many as 3.5% of total somatic inpatient days during the years 2011 and 2012. The 
incidence is considerably higher than the previous Norwegian estimate from 1999, 
most prevailing among the elderly, and significantly higher among men than women. 
Based on official population projections from Statistics Norway (Figure 5) there is 
reason to believe that this trend will continue throughout the coming years. Further, we 
have shown that sepsis is contributing to a high number of hospital deaths, implying 
that improvements in treatment and survival could influence population mortality in 
the future. It is thus desirable that sepsis receives greater attention in official 





Figure 5: Norwegian population projections for inhabitants 60 to 99 years of age in 




Sepsis is a medical emergency and has traditionally been associated with critical care 
settings. We have shown that a large proportion of sepsis patients never receive 
intensive care treatment and we have described this cohort and their ICU-treated 
counterpart. Although we were not able to severity stratify the respective cohorts to 
















care priorities. Considering the different mortality rates in favor of the non-ICU group, 
we find reason to encourage the allocation of selected sepsis patients to high 
dependency units; yet there is still need for future studies accounting for illness 
severity. On the other hand, we found several points that need improvement when 
evaluating the handling of sepsis patients at admission to our emergency department. 
Areas that should receive thorough attention are identification and handling of less 
frequent infection categories (i.e. not respiratory and urinary tract infections), 
including proper microbiological sampling and choice of empirical treatment, as well 
as the effort put into the oldest sepsis patients.  
 
Throughout the current work we have highlighted several important limitations of 
existing research in the field of sepsis epidemiology. However, irrespective of these 
weaknesses there is no doubt that sepsis is one of the most common forms of severe 
illness today. Its clinical presentation and disease course is variable, influenced by 
multiple qualities such as the causative pathogen, host factors, preexisting medication 
and the timing and nature of provided care. The common denominator is a 
dysregulated host response to infection, where increasing insight into its underlying 
processes now points towards an area of personalized medicine for sepsis patients 
[59]. Already a decade ago, prominent researchers called for a rethinking in this 
direction [224]. Interesting concepts include endothelial and epithelial barrier 
recovery, mitochondrial sparing agents, immune-stimulating agents to resolve 
immunosuppression, extracorporeal blood purification techniques to control 
hyperinflammation, and other strategies to clear extracellular histones that are 
important parts of the DAMP response (Figure 6) [39, 221, 225, 226]. Hopefully this 






Figure 6: Host immune response to sepsis and impact of immunomodulation 
therapies. Continuous lines: possible patient immune status; dotted lines: potential 
effects of therapies; BP: blood purification techniques; IS+: immunostimulant drugs. 
Copyright © 2016 Springer International Publishing Switzerland,  





Nevertheless, sepsis is indisputably an infectious disease, where antimicrobial 
treatment will always be of paramount importance. Efforts to reduce the development 
of resistant microbes are now more important than ever before. In the end, the greatest 
challenge in sepsis will not only remain, its relevance will increase in parallel with the 
forthcoming expansion of the elderly population (Figure 5). That is to know when to 
keep hands-off and remember a famous statement by John C. Marshall:  
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- The word multivariate is used instead of multivariable.   
- There is an error in the estimated rate of sepsis patients per 1000 hospital admissions, 
which is corrected in the summary of the results herein. The reason for this was an 
incorrect denominator which included day patient stays in addition to overnight 
admissions. In this relation, we acknowledge that “hospital incidence” is no formal 
term, and have therefore now presented the percentage of sepsis admissions among 
total somatic hospitalizations in patients >15 years.  
- The interpretation of ORs is incorrect in the section Antimicrobial agents, where the 
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Abstract
Background: Severe sepsis is recognized as an inflammatory response causing organ dysfunction in patients with
infection. Antimicrobial therapy is the mainstay of treatment. There is an ongoing demand for local surveillance of
sepsis aetiology and monitoring of empirical treatment recommendations. The present study was established to
describe the characteristics, quality of handling and outcome of patients with severe sepsis admitted to a
Norwegian university hospital.
Methods: A one year prospective, observational study of adult community acquired case-defined severe sepsis was
undertaken. Demographics, focus of infection, microbiological findings, timing and adequacy of empirical antimicrobial
agents were recorded. Clinical diagnostic practice was evaluated. Differences between categorical groups were
analysed with Pearson’s chi-squared test. Predictors of in-hospital mortality were identified in a multivariate
stepwise backward logistic regression model.
Results: In total 220 patients were identified, yielding an estimated annual incidence of 0.5/1000 inhabitants. The
focus of infection was established at admission in 69%. Respiratory tract infection was present in 52%, while
genitourinary, soft tissue and abdominal infections each were found in 12-14%. Microbiological aetiology was
identified in 61%; most prevalent were Streptococcus pneumoniae, Escherichia coli and Staphylococcus aureus.
Independent predictors of in-hospital mortality were malignancy, cardiovascular disease, endocarditis, abdominal
infections, undefined microbiological aetiology, delay in administration of empirical antimicrobial agents ≥ 6 hours and
use of inadequate antimicrobial agents. In patients ≥ 75 years, antimicrobial therapy was less in compliance with current
recommendations and more delayed.
Conclusions: Community acquired severe sepsis is common. Initial clinical aetiology is often revised. Compliance with
recommendations for empirical antimicrobial treatment is lowest in elderly patients. Our results emphasizes that quick
identification of correct source of infection, proper sampling for microbiological analyses, and fast administration of
adequate antimicrobial agents are crucial points in the management of severe sepsis.
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Background
Sepsis is recognized as a dysregulation of the inflamma-
tory response in patients with infection. Progression to
severe forms with organ dysfunction develops in one
out of three patients, commonly resulting in long-term
hospitalization and death [1,2]. Algorithms for identi-
fication and management of severe infection hence
emphasize recordings of vital signs and laboratory data,
aiming at discovering circulatory failure and other organ
dysfunctions at an early stage [3,4]. In recent years, one of
the main focuses in sepsis related research has been on
candidate biomarkers in the host and their possible role
in targeted therapy. However, definite novel therapeutic
approaches have not been established and optimized
anti-infective therapy is still the mainstay of treatment
in severe sepsis. Delayed administration of the initial
dose of antimicrobial agents, the adequacy of antimicro-
bial therapy and, where applicable, delayed surgical
source control, are all independent prognostic factors
[5-8]. Care bundles with guidance on how to diagnose
and handle affected patients, including up-to-date recom-
mendations on empirical treatment, therefore emerges
as one of the most important measures to improve out-
comes in sepsis. In 2007, Llewelyn and Cohen addressed
the relevance of monitoring the microbial epidemiology
of sepsis on a local basis [9]. Based on such knowledge,
empirical recommendations may be customized. Accord-
ingly, we established the present study of adult community
acquired severe sepsis to describe the occurrence, charac-
teristics and handling of affected patients admitted to our
hospital. Secondary objectives were to evaluate our physi-
cians’ compliance with local guidelines and to identify po-
tential predictors of in-hospital mortality in severe sepsis.
Methods
Study setting
Haukeland University Hospital is serving as a local hos-
pital with approximately 350.000 inhabitants in the
catchment area. It is also a tertiary care referral center
in western Norway, with a population of 1.1 million in-
habitants. The current investigation was a one year pro-
spective, case defined observational study of patients
hospitalized in the period from January 1st through
December 2008. Enrollment of patients took place in
the high dependency unit at the Division for infectious
diseases, Department of Medicine, in the general intensive
care unit (ICU) at the Department of Anesthesia and
Intensive care, and in the combined intensive care and
high dependency unit at the Department of Cardiology.
Patient selection
All subjects transferred from the emergency department
(ED) to any of the three units were screened for severe
sepsis according to consensus criteria [3,4]. Patients
older than 15 years of age hospitalized due to commu-
nity acquired infection, including patients transferred
from affiliated hospitals, were included if they developed
severe sepsis within 24 hours of admission to the primary
institution. Five patients were not recognized within
24 hours, but suspected to have non-infectious con-
ditions. However, they were identified with delay and
included, as their fulfillment of inclusion criteria within
the first 24 hours of hospitalization was documented.
Daily screening in the three units involved were per-
formed. Patients were evaluated for eligibility by use of
admission records, patient charts and inquiries with
senior physicians at the respective wards. All of the
eligible subjects were discussed in consensus meetings
within the group of co-authors before a final decision
of inclusion was made.
Data collection and follow-up
Clinical data were registered prospectively until hospital
discharge or in-hospital death, using predefined case re-
port forms. Information was collected from medical re-
cords, patient charts, and the intensive care electronic
monitoring system IntelliVue Clinical Information
Portfolio (ICIP, Philips Medical Systems, Eindhoven,
the Netherlands). The following parameters were re-
corded at admission; time and date, department affili-
ation, demographics, comorbidities, suspected focus of
infection, heart rate, respiratory rate, blood pressure, body
temperature and Glasgow coma scale (GCS). Laboratory
results were registered continuously. During the follow-
up, data on organ dysfunction and adjunctive sepsis ther-
apies was recorded. Timing and adequacy of antimicrobial
agents was evaluated together with their appropriateness
according to local recommendations. Results from blood
cultures and microbiological analyses of urine, abscess
drainage, sputum, feces and cerebrospinal fluid were col-
lected. Possible contaminants of samples were excluded
from analysis. Antimicrobial susceptibility patterns of
cultured pathogens were registered when available. At
discharge a final diagnosis was established by one con-
sultant (SS), based on retrospective evaluation of all
available records, clinical, microbiological, laboratory
and medical imaging data. Data from medical records
and patient charts was verified before it was entered in
a local database. The main outcome measure was the
in-hospital case fatality rate (CFR). We also calculated
the 28-day all-cause mortality rate. Long-term survival
was assessed after four years.
Calculation of incidence and mortality rate
The population incidence and the 28-day all-cause mor-
tality rate was calculated based on the number of inhabi-
tants > 15 years in the local catchment area in the year
2008. Patients transferred from affiliated hospitals were
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excluded from this estimation. Incidence per hospital
admissions was calculated from total cases in the study.
Statistical analyses
Data were analyzed using PASW Statistics 18 software
(SPSS Inc., Chicago, Ill. USA). Differences between cat-
egorical groups were analyzed with Pearson’s chi-squared
test (χ2). To identify predictors of outcome, univariate lo-
gistic regression analyses of factors previously reported to
be associated with mortality was performed. Variables with
P values < .10 were entered into a multivariate stepwise
backward model. Results from the logistic regression ana-
lyses are reported as odds ratios (ORs) with 95% confi-
dence intervals (CIs) from the unadjusted (univariate)
models, the fully adjusted model (step 1 in backward step-
wise regression), and final model (4th and last step in
backward stepwise regression) with p-values from the like-
lihood ratio test. For the latter two models the results of
Hosmer-Lemeshow’s goodness-of-fit-test are reported. All
variables in the logistic regression analyses presented in
table form are categorical. We additionally tested for
linear trend across age groups with 15 years intervals,
with time to administration of the initial antimicrobial
agents assessed as a continuous variable measured in
hours (with exclusion of two extreme outlying values
> 100 hours) and with time assessed as a continuous vari-
able after logarithmic transformation. Long-term survival
was compared across age groups by a Kaplan-Meier plot
with log rank computation results. Overall, two sided P
values < 0.05 were considered significant.
Ethical considerations
The study was approved by the Regional Committee for
Medical and Health Research Ethics, Health Region
West (REK-Vest, case number 2010/165).
Results
Base-line characteristics
A total of 220 patients with community acquired severe
sepsis were identified, corresponding to an annual in-
cidence of 2.2/1000 hospital admissions and 0.5/1000
inhabitants. Median age was 67 years and there was a
small predominance of male patients (53%). Significant
comorbidity was present in 90%.
Focus of infection
A final clinical diagnosis was established in all patients
at discharge (Table 1). At admission, the correct primary
focus of infection was identified in 69%. The focus was
considered unidentified in 16%, an incorrect focus was
suggested in 11%, whereas the remaining 4% were not
suspected to have infection at admission.
The level of diagnostic precision differed depending
on the nature of the infection. Respiratory tract infection
(RTI) was e.g. suspected in 101 subjects at admission, of
whom 93 were later confirmed while 8 turned out to
have another focus. Overall, RTI was verified in 115 pa-
tients and among these, 22 cases were missed at admis-
sion. As follows, 81% of actual RTIs were assigned with
a correct diagnosis in the ED. In the less frequent causes
of sepsis the level of precision was lower (Table 1).
Microbiology
Microbiological tests were performed in 212 of 220 pa-
tients. A plausible pathogen was identified in 61% of tested
subjects, with a total of 171 positive tests all together
(Table 2). Gram-positive microbes constituted 57%. Over-
all, Streptococcus pneumoniae was most prevalent, closely
followed by Escherichia coli, Staphylococcus aureus and
alpha hemolytic streptococci. Blood cultures were ob-
tained in 198 cases. Of these, 37% were positive, most
often with E. coli, S. pneumoniae or S. aureus respectively.
Table 1 Suspected, confirmed and proportion of correct identified focus of infection in community acquired severe
sepsis (n (%))
Infection Suspected at admissiona Confirmed at dischargea Correct at admissionb
Respiratory 101 (45.9) 115 (52.3) 93 (80.9)
Genitourinary 25 (11.4) 31 (14.1) 20 (64.5)
Soft tissue 23 (10.5) 27 (12.3) 18 (66.7)
Abdominal 16 (7.3) 26 (11.8) 13 (50)
Endocarditis 4 (1.8) 12 (5.5) 4 (33.3)
Bacteremia 2 (0.9) 5 (2.3) 1 [20]
CNS 4 (1.8) 4 (1.8) 2 (50)
Unknown 36 (16.4) 0 (0.0) n.a.
Not suspected 9 (4.1) n.a. n.a.
Total 220 (100) 220 (100) 151 (68.6)
Abbreviations: CNS, central nervous system; n.a., not applicable.
aPercent calculated column-wise, from total cases.
bPercent calculated row-wise, from each infection category’s total number of confirmed cases.
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Among the most prevalent bacteria, resistance towards
empirical antimicrobial regimens was observed in two iso-
lates only. Both were ESBL-producing E. coli. Polymicro-
bial infections were found in 19% of test-positive patients,
namely in eight soft tissue infections (STIs), six abdominal
infections, six RTIs (aspiration in all cases) and four geni-
tourinary infections (GUIs). Figure 1 shows the relation-
ship between the focus of infection and the proportion of
patients with confirmed microbiological aetiology. Fifteen
subjects received antimicrobial treatment prior to hos-
pitalization. Microbiological samples were obtained from
all of them, yet a plausible pathogen was identified in only
five cases.
Antimicrobial agents
Table 3 outlines the initial choice of empirical antimicro-
bial agents and the physicians’ compliance with the rec-
ommendations for empirical treatment of severe sepsis
Table 2 Microbiological aetiology in community acquired severe sepsis (n)
Total Blood Urine Abscess drainage Other
Gram-positivea 90 44 27 25 18
Streptococcus pneumonia 29 14 20b 0 5
Alpha hemolytic streptococci 18 7 0 6 7
Group A/C/G streptococci 13 6 0 9 1
Group B streptococci 2 1 0 1 0
Enterococci 6 3 2 0 2
Staphylococcus aureus 20 11 4 9 3
Staphylococcus caprae 1 1 0 0 0
Aerococcus viridans 1 1 1 0 0
Gram-negativea 55 32 21 8 9
Escherichia coli 27 19 13 3 3
Klebsiella 10 6 5 0 1
Enterobacter 1 1 0 0 0
Proteus 2 0 0 1 1
Other Enterobacteriaceae 5 2 3 1 0
Pseudomonas aeruginosa 2 1 0 1 1
Stenotrophomonas maltophilia 1 0 0 1 0
Neisseriae meningitides 2 2 0 0 0
Haemophilus influenzae 2 1 0 0 1
Haemophilus parainfluenzae 2 0 0 0 2
Unspecified gram negative rods 1 0 0 1 0
Anaerobic bacteria 17 6 0 3 9
Clostridium species 5 2 0 0 3c
Bacteroides species 5 3 0 1 2
Prevotella 4 0 0 2 2
Slackia exigua 1 1 0 0 0
Fusobacterium 1 0 0 0 1
Unspecified gram positive rods 1 0 0 0 1
Other 9 0 0 3 6
Candida species 7 0 0 3 4
Aspergillus species 1 0 0 0 1
Influenzavirus A 1 0 0 0 1
Patients with ≥1 positive test 129 74 40 23 29
Unless otherwise specified, numbers shown are all isolated microorganisms in category.
aAnaerobic species not included.
bPositive antigen tests in all 20 cases (14 cases were detected in antigen tests only).
cDetection of Clostridium difficile toxin A in all cases.
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at our hospital in 2008. Considering the suspected focus
of infection at admission, the empirical choice of anti-
microbial therapy was correct in 81% of the cases. Com-
pliance with the recommendations was lower when
patients were ≥ 75 years of age (χ2 P = 0.029). When
comparing the initial given agent with the confirmed
focus at discharge, 76% had received empirical treatment
appropriate for their final diagnosis. Susceptibility tests
revealed that in the group with defined microbiological
aetiology (n = 129), 82% had been treated with adequate
antimicrobial therapy from the first dose. Compliance
with the recommendations proved to have been better
when adequate therapy was given, in comparison to
when inadequate therapy was given (83% vs. 44%, χ2 P <
0.001).
Median delay before administration of the initial dose
of antimicrobial therapy was 2.8 hours after hospital ad-
mission. Compared to subjects with RTI, the delay was
highest in abdominal infections (2.5 hours vs. 6.9 hours).
Patients in the latter category had a 4.5 times greater
risk of receiving their initial dose after more than six
Figure 1 Microbiological identification rates in different
infection categories (n). Relationship between focus of infection and
the proportion of patients with confirmed microbiological aetiology.
The most prevalent microbe was in RTI (respiratory tract infection);
Streptococcus pneumoniae (28/43), GUI (genitourinary infection);
Escherichia coli (16/28), STI (soft tissue infection); Group A/C/G
streptococci (10/23), ABD (abdominal infection); Escherichia coli (8/15),
and AIE (acute infectious endocarditis); Staphylococcus aureus (5/12).
Table 3 Choice of empirical antimicrobial regimen according to suspected and confirmed focus of infection and
compliance with recommendations (n/n (%))
Focus of infection with recommended
regimen
Suspected focus at admission
Total cases/Cases with correct regimena
Confirmed focus at discharge
Total cases/Cases with appropriate regimena
Respiratoryb,c 100d/82 (82.0) 115d/96 (83.5)
penicillin G and ciprofloxacin or
penicillin G and gentamicine,f
Genitourinary 25d/20 (80.0) 30d/24 (80.0)
ampicillin and gentamicinf
Soft tissue 23/18 (78.3) 27d/18 (66.7)
penicillin G and clindamycin (+/− gentamicin)
Abdominal 16d/11 (68.8) 26d/13 (50.0)
ampicillin and gentamicin and metronidazol or
3rd generation cephalosporin and metronidazol or
piperacillin-tazobactam or
meropenem
Endocarditis 4/3 (75.0) 12/7 (58.3)
penicillin G and gentamicin or
3rd generation cephalosporin
CNS 4/3 (75.0) 4/4 (100)
penicillin G and 3rd generation cephalosporin
Unknown/bacteremia 38d/34 (89.5) 5/5 (100)
penicillin G and gentamicin (+/− metronidazol)e,f
Total 210/171 (81.4) 219/167 (76.3)
aCorrect and appropriate regimen according to recommendations for empirical antimicrobial therapy in Haukeland University Hospital in 2008.
bOne patient with a suspected and later verified respiratory tract infection died before antimicrobial therapy was implemented.
cSuspected atypical pneumonia: macrolide or doxycycline is added.
dNumber of correct cases including one patient given meropenem as initial agent (n = 4 in total).
eIf allergic to penicillin: clindamycin.
fIf gentamicin is contraindicated: 3rd generation cephalosporin monotherapy.
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hours of hospitalization (95% CI 1.8-11.0, χ2 P = 0.005).
Moreover, patients ≥ 75 years of age had a 2.3 times
greater risk of receiving antimicrobial therapy beyond
six hours compared to younger patients (95% CI 1.2-
4.4, χ2 P = 0.008). Among cases with no suspicion of in-
fection at admission, the delay was 13 – 75 hours.
Outcome
Table 4 shows case fatality rates (CFRs) for subgroups of
patients and predictors of outcome in uni- and multi-
variate logistic regression analyses. High CFRs were seen
in patients with malignancy or cardiovascular disease. In
the multivariate analysis, patients with confirmed endo-
carditis and abdominal infections had a significantly
greater risk of death compared to RTI. Detection of
microbiological aetiology and adequate antimicrobial
treatment increased survival. Mortality was increased
when antimicrobial agents had been given before hos-
pital admission and when time to administration of the
initial in-hospital dose of antimicrobial agents was more
than six hours. There were not significant results in
multivariate analyses with cut-offs below six hours or
when testing for linear trend in mortality according to
hourly increasing delays of antimicrobial agents. When
limiting the latter analysis to patients receiving appropri-
ate empirical therapy (adequate antimicrobial agents in
cases with detection of a plausible pathogen, and correct
empirical antimicrobial agents according to Hospital
guidelines in patients with no detection of a pathogen,
n = 178) there was a small significant impact also in
multivariate analysis (p = 0.001, OR 1.06, 95% CI: 1.02 to
1.09). In univariate analyses, patients with a correctly
identified source of infection at admission and patients
receiving appropriate empirical antimicrobial agents ac-
cording to Hospital guidelines had a higher chance of
survival. However, these findings could not be validated
by multivariate analysis. A tendency towards greater
mortality with increasing age was observed, but was
not statistically significant. Replacing age categories in
Table 4 with trend across age groups provided a similar
non-significant result in multivariate analysis, as did
categorization of patients into two groups on the basis
of age below versus ≥75 years. Total in-hospital CFR in
this study was 25%. The 28-day CFR was 24.5% and the
28-day all-cause mortality rate was 13/100 000 inhabitants
per year. One-year mortality was 34.5%. A Kaplan-Meier
curve on survival is presented in Figure 2.
Discussion
We estimated the annual incidence of community ac-
quired severe sepsis in our hospital to be 2.2/1000 ad-
missions and 0.5/1000 inhabitants. In-hospital mortality
was 25% and the 28-day all-cause mortality rate was 13/
100 000 inhabitants per year.
Previous data on the occurrence of sepsis in Norway is
limited to a retrospective study using data from the Nor-
wegian Patient Registry, in which the total incidence of
severe sepsis was calculated to 3.0/1000 admissions and
0.47/1000 inhabitants [10]. In contrast to this study, we
did not include nosocomial sepsis which constitutes ap-
proximately 50% of all cases [5,6,11-14]. During three
months prior to the present study we performed a pro-
spective pilot survey of case-defined sepsis in our ED.
Subsequent comparison with cases identified retrospect-
ively by discharge ICD-10 codes revealed that 50% of all
sepsis-cases were missed when using the retrospective
method alone (Nygård, unpublished results). Thus, the
calculation in our current prospective study probably
represents a more accurate estimation of the Norwegian
incidence of community acquired severe sepsis than previ-
ous results. Previous prospective studies with systematic
inclusion from both ICUs and non-ICUs, reporting details
on the occurrence of severe sepsis, are to our knowledge
limited to a single survey from Spain [15]. They calculated
an annual incidence of 1.0/1000 inhabitants, including
nosocomial cases. Other studies of community acquired
severe sepsis have used different methods for patient in-
clusion, and many do not offer data on incidence or are
not applicable for such purpose [16-22].
The respiratory tract was the most frequent origin of
infection in our patients. This is consistent with results
from other studies [5,11-14,23-25]. We diagnosed ab-
dominal infections less frequently, while GUI and STI
were found more often than in many previous reports
[6,11-13,25-27]. However, studies with inclusion of pa-
tients treated outside ICUs have found a distribution of
diagnoses more similar to ours [15,16,23,28,29]. Patients
with abdominal infections have been shown to have a
high demand for intensive care treatment [11]. There
are in addition more abdominal infections in nosocomial
compared to community acquired sepsis [15,30]. In our
study most patients with this diagnosis were treated in
an ICU, whereas patients with GUI on the contrary
mainly were treated outside ICUs. Moreover, patients
with abdominal infection had a prolonged length of stay
(data not shown). In many studies on sepsis epidemi-
ology, frequencies are estimated on the basis of preva-
lence data from ICUs only. Together, these observations
suggest that distribution of various infections is influ-
enced by study design, e.g. our low occurrence of ab-
dominal infections is likely conditional to inclusion of
patients from outside ICUs.
A likely pathogen has been found in 60-75% of eligible
subjects in other studies on sepsis [5,6,13,19,24,31],
comprising positive blood cultures within the range of
22-37% [5,6,12,19,30-33]. This is comparable to our data.
In line with related observations, we identified more
Gram-positive than Gram-negative bacteria [1,12,24].
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Characteristic n n (%) OR 95% CI P value OR 95% CI P value OR 95% CI P value
Gender 0.240
Male 117 33 (28.2) 1.00 Reference
Female 103 22 (21.4) 0.69 (0.37, 1.29)
Age (years) 0.065 0.619
16-30 18 1 (5.6) 1.00 Reference 1.00 Reference
30-45 22 4 (18.2) 3.78 (0.38, 37.28) 0.99 (0.07, 14.18)
45-60 36 8 (22.2) 4.86 (0.56, 42.30) 2.27 (0.19, 26.64)
60-75 68 16 (23.5) 5.23 (0.65, 42.43) 2.88 (0.28, 29.54)
≥75 76 26 (34.2) 8.84 (1.11, 70.18) 3.09 (0.28, 33.54)
Comorbidity
None 23 1 (4.3) 0.12 (0.02, 0.92) 0.005
Hypertension 91 18 (19.8) 0.61 (0.32, 1.17) 0.130
Cardiovascular 107 35 (32.7) 2.26 (1.20, 4.24) 0.010 2.18 (0.85, 5.61) 0.101 3.29 (1.45, 7.48) 0.003
Pulmonary 61 14 (23.0) 0.86 (0.43, 1.72) 0.662
Diabetes 38 9 (23.7) 0.92 (0.40, 2.08) 0.836
Malignancy 31 13 (41.9) 2.53 (1.15, 5.58) 0.025 5.97 (1.96, 18.19) 0.001 5.50 (1.92, 15.78) 0.001
Dementia 17 6 (35.3) 1.71 (0.60, 4.88) 0.324
Psychiatric 51 9 (17.6) 0.57 (0.26, 1.27) 0.155
Substance abuse 31 6 (19.4) 0.69 (0.27, 1.77) 0.423
Otherd 74 27 (36.5) 2.42 (1.29, 4.53) 0.006 2.52 (1.11, 5.70) 0.025 2.43 (1.10, 5.35) 0.026
Correct suspected focus of infection 0.020 0.606
Yes 152 31 (20.4) 1.00 Reference 1.00 Reference
No 68 24 (35.3) 2.13 (1.13, 4.02) 0.79 (0.33, 1.91)
Confirmed focus of infection 0.007 0.003 0.001
Respiratory 115 25 (21.7) 1.00 Reference 1.00 Reference
Genitourinary 31 4 (12.9) 0.53 (0.17, 1.67) 0.41 (0.08, 2.21) 0.47 (0.09, 2.39)
Soft tissue 27 6 (22.2) 1.03 (0.38, 2.82) 2.04 (0.55, 7.60) 2.42 (0.68, 8.68)
Abdominal 26 12 (46.2) 3.09 (1.27, 7.51) 2.95 (0.87, 10.03) 3.54 (1.09, 11.43)
Endocarditis 12 7 (58.3) 5.04 (1.47, 17.25) 17.43 (2.74, 111.06) 18.94 (3.45, 104.06)
Bacteremia 5 0 (0.0) 0.00 (0.00, ) 0.00 (0.00, ) 0.00 (0.00, )
CNS 4 1 (25.0) 1.20 (0.12, 12.04) 9.22 (0.71, 118.97) 7.66 (0.63, 93.73)
Microbiological samples 0.008 0.028 0.025
Positive 129 24 (18.6) 1.00 Reference 1.00 Reference 1.00 Reference
Negative 83 26 (31.3) 2.00 (1.05, 3.79) 3.58 (1.34, 9.55) 3.34 (1.29, 8.63)
Not obtained 8 5 (62.5) 7.29 (1.63, 32.63) 2.91 (0.35, 24.09) 4.44 (0.60, 32.95)
Empirical antimicrobial agents
Suspected focus of infection 0.433
Appropriate compliance 171 38 (22.2) 1.00 Reference
Inappropriate compliance 39 11 (28.2) 1.38 (0.63, 3.02)
Confirmed focus of infection 0.027 0.241
Appropriate 168 35 (21.0) 1.00 Reference 1.00 Reference
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Antigen- and toxin tests were included in our analysis
of microbiological aetiology. A positive urinary antigen
assay was the only laboratory documentation in 48% of
subjects with S. pneumoniae. This is in accordance with
a prospective report on community acquired pneumo-
nia, where 44% of 171 cases with S. pneumoniae were
diagnosed by urinary antigen detection alone [34]. In
Norway, guidelines for pneumococcal vaccination of
adults ≥ 65 years and pre-defined younger persons at risk
have been established since 1996, but vaccine coverage
has not been satisfactory. However, a pneumococcal
conjugated vaccine has been a part of the routine vac-
cination program for children with nearly completely
coverage since 2006. From this point there has been a
marked decline in the number of cases with invasive
S. pneumoniae, also among adults. Thus, the propor-
tion of patients with severe sepsis originating from this
microbe is probably decreasing.
The proportion of patients with detection of a plausible
pathogen differed among the various origins of infection
in our study. The detection rate was low in RTI and ab-
dominal infection in particular. This is also previously
Table 4 In-hospital mortality in patients with community acquired severe sepsis at Haukeland University Hospital in
2008 (Continued)
Inappropriate 52 19 (36.5) 2.17 (1.10, 4.27) 0.79 (0.33, 1.91)
Microbiological aetiologye < 0.001
Adequate 106 12 (11.3) 1.00 Reference
Inadequate 23 12 (52.2) 8.55 (3.10, 23.58)
In-hospital initial dose administered 0.002 0.051 0.046
<6 hours after admission 157 30 (19.1) 1.00 Reference 1.00 Reference 1.00 Reference
≥6 hours after admission 54 22 (40.7) 2.91 (1.49, 5.71) 2.52 (1.00, 6.38) 2.48 (1.02, 6.02)
Pre-hospital administration 0.059 0.055 0.041
No 205 48 (23.4) 1.00 Reference 1.00 Reference 1.00 Reference
Yes 15 7 (46.7) 2.86 (0.99, 8.30) 4.13 (0.99, 17.21) 4.20 (1.08, 16.39)
Abbreviations: OR: odds ratio; CI: confidence interval.
an = 220.
bIncludes all categories with P < 0.10 in the unadjusted analyses; n = 211; Hosmer-Lemeshow’s chi-square = 12.38, df = 8, P = 0.135.
cFrom backward stepwise selection at significance level 0.05; n = 211; Hosmer-Lemeshow’s chi-square = 3.18, df = 8, P = 0.923.
dIncluding chronic kidney, liver and rheumatic diseases.
eNot included in multivariate analysis due to a substantial number of not applicable cases (if included, significant in multivariate analysis).
Figure 2 Long-term survival after community acquired severe sepsis. Kaplan-Meier curve on survival after community acquired severe sepsis
in different age groups. Follow-up was four years after hospital admission for all 220 patients. Survival in all three groups were significant different
according to Log rank test results (P = 0.000 in analysis of age group 16–50 vs. 50–75 and P = 0.001 in analysis of age group 50–75 vs. ≥75). Overall,
four-year mortality was 55.5%.
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documented [20,31]. Patients with negative microbio-
logical samples had a significant greater risk of death than
patients with positive samples. Although not significant in
all categories, this result is consistent when stratification
of infection categories is performed, supporting that the
increased risk of death in cases with negative samples was
retained throughout our multivariate model. Detection of
a plausible pathogen gives the opportunity to administer
validated adequate antimicrobial treatment. In subjects
with negative microbiological samples, correct antimicro-
bial therapy can be delayed or not provided. An increased
risk of death has been demonstrated in patients with se-
vere infection receiving inadequate antimicrobial therapy
[6,7,35-37]. In many of these studies multiresistant iso-
lates were often encountered. We identified no isolates
of MRSA, MRSE or VRE, and only two cases of ESBL-
producing Gram-negative bacilli (of which one was even
suspected, and treated accordingly, at admission). On
the contrary, S. pneumoniae and E. coli were frequently
identified. The CFRs in these two categories were low;
7 and 18.5% respectively (data not shown). Hence, a
possible contributor to the different risk of death among
patients with positive versus negative microbiological
samples might be our high frequency of microbes with
unproblematic resistance properties. Inability to tailor
treatment with effective antimicrobial agents might also
have influenced outcomes of the patients which re-
ceived pre-hospital antimicrobial agents. In a study by
Garnacho-Montero et al., previous antibiotic therapy
within the last month was independently related to ad-
ministration of inadequate antimicrobial therapy [6].
We were able to demonstrate a correlation between
correct use of empirical antimicrobial agents and suscep-
tibility in detected pathogens. It is therefore of concern
that one in five patients did not receive the recom-
mended regimen. One possible explanation for this is
that sepsis is diagnosed on the basis of unspecific cri-
teria, independent of primary focus, microbiological aeti-
ology and host factors. Current diagnostic algorithms
focus on identifying complications of an infection ra-
ther than its aetiology. The level of precision in estab-
lishing the focus of infection was variable and often low
in our study. Only 17 of 38 patients with confirmed ab-
dominal infection or endocarditis were assigned with
the correct focus, and half of them received initial
treatment as recommended. The longest delays before
initiation of antimicrobial therapy were found in these
two groups, and their hospital mortality was high. An
evaluation of the quality of clinical diagnostic practice
in severe sepsis, comparing the suspected focus at
admission with a confirmed diagnosis at discharge, has
to our knowledge not been published previously. We
identified severe sepsis in nine subjects not suspected
with infection at admission. Opposite, a study of the
aetiology of illness in suspected severe sepsis found that
18% of the patients had noninfectious diagnoses mim-
icking sepsis [20]. Seen together these observations
suggest a two-sided limitation in commonly used sepsis
algorithms.
We found that a six hour delay or more in administra-
tion of the initial dose of antimicrobial treatment was as-
sociated with an increased risk of death, but could not
demonstrate independent impact on mortality during
the preceding hours, as reported by Kumar et al. in a
study of patients with septic shock [5]. Other studies
investigating the impact of early administration of anti-
microbial therapy have also failed to demonstrate an
hourly decrease in survival [36,38]. Some have demon-
strated beneficial effects on survival with administration
of antimicrobial therapy within the first hour [36,39].
Kumar et al. limited their inclusion to cases given effect-
ive antimicrobial therapy. Likewise, the beneficial effect
found by Gaieski et al. was significant only when anti-
microbial therapy was considered appropriate [36]. Ana-
lyses of our data with the same limitations as Kumar
and Gaieski resulted in significant impact of hourly in-
creasing time to administration of antimicrobial agents
on mortality in multivariate analysis. However, the
hourly effect was low. Since we have included a broad
selection of the population with severe sepsis, ranging
from septic shock to cases with other and less severe
organ dysfunctions, our results concerning timing is in-
evitably influenced by the different levels of severity in
our population. We were not able to severity stratify our
patients and cannot investigate this matter any further.
In patients ≥ 75 years, antimicrobial therapy was less
in compliance with current recommendations and more
delayed. An age dependent risk of in-hospital mortality
has been demonstrated in severe infection [40]. Follow-
ing the results in our study, we question whether this
is solely caused by host factors. Increasing age did not
emerge as an independent risk factor. Subjects ≥ 75 years
had on average one additional comorbidity, a significant
higher presence of cognitive impairment and a signifi-
cant higher creatinine level at admission than younger
patients (data not shown). These data indicates that there
were more potentially complicating factors among elderly
patients. However, our Hospital guidelines are clear in
terms of instructions on adjusting the doses of anti-
microbial agents when needed, as well as recommend-
ing alternative treatment if the primary choice of drug is
contraindicated. This was taken into account when we
evaluated the level of compliance. Hence, we consider
that there is room for improvements in the handling of
our elderly patients, especially given the small difference
in mortality after hospital discharge between patients
aged 50–75 versus ≥75 years during the long-term
follow-up (Figure 2).
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Strengths and limitations
Major strengths of this study are the prospective design,
inclusion throughout an entire year, a small group of
dedicated investigators and recruitment of patients from
both ICUs and non-ICUs. Major limitations are the sam-
ple size and a lack of severity stratification of the included
patients. Consequently, statistical results are encumbered
with uncertainties. Due to the high number of explanatory
variables included in the logistic regression analysis and
the screening and stepwise selection of variables in the re-
ported results, over fitting is most likely present in the
final model reported. As no formal adjustment for mul-
tiple testing has been performed, most emphasize should
thus be given to the most significant predictors (i.e. with
P < 0.01).
Conclusion
We have found a high incidence of community ac-
quired severe sepsis in a Norwegian university hospital.
Initial clinical aetiology was often revised and the diag-
nosis sometimes overlooked in the emergency department.
Adequate antimicrobial therapy improved outcome, while
undefined microbiological aetiology, endocarditis, ab-
dominal infections and delayed administration of anti-
microbial agents increased the risk of death. A need for
improved handling of elderly patients was identified.
Our results emphasizes that quick identification of cor-
rect source of infection, proper sampling for microbio-
logical analyses, and fast administration of adequate
antimicrobial agents are crucial points in the manage-
ment of severe sepsis.
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Background: Most studies of sepsis are from intensive care units
(ICUs). We aimed to investigate community-acquired severe sep-
sis in a broader population, in order to compare patients treated
in or outside an ICU .
Methods: We performed a 1-year prospective observational
study with enrollment of patients from three units; a general ICU,
a combined ICU/non-ICU and a medical ward with limited
surveillance facilities. Hospital survivors were followed up for
5 years.
Results: Overall, 220 patients were included, of which 107
received ICU treatment. The majority of abdominal (77%,
P = 0.003) and genitourinary (81%, P < 0.001) infections were
found in ICU and non-ICU patients, respectively. Time to first
antibiotic administration was longer in ICU-patients (median 3.5
vs. 2.0 h in non-ICU patients, P = 0.011). ICU developed more
organ dysfunctions than non-ICU patients (P < 0.001), neverthe-
less supportive therapy with vasoactive drugs and non-invasive
ventilation was documented in 22% and 27% of the latter. Med-
ian hospital length of stay was 15 vs. 9 days (P = 0.001), and hos-
pital and 5-year mortality rates 35% vs. 16% (P = 0.002) and 57%
vs. 58% (P = 0.892) among ICU and non-ICU patients, respec-
tively. Increasing age (HR 1.06 (1.04, 1.07) per year, P < 0.001),
not care level during hospitalization (HR 1.19 (0.70, 2.02),
P = 0.514), influenced long-term survival.
Conclusion: Half of the subjects with community-acquired severe
sepsis never received ICU treatment. Still, use of organ supportive
therapy outside the ICU was considerable. Hospital mortality was
higher, whereas 5-year survival was similar when comparing ICU
with non-ICU patients.
Editorial Comment:
This study examined the course of patients with sepsis who did not receive treatment in the ICU.
Approximately half of sampled patients meeting these (sepsis) diagnosis criteria received their
care outside of the ICU. When compared to a simultaneous ICU-treated sepsis cohort, the long-
term survival was similar.
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ORIGINAL ARTICLE
Severe sepsis is a major cause of long-term hospi-
talization and morbidity, recently estimated to
contribute to one in every two to three hospital
deaths in the United States.1 Most of the studies
regarding this condition have been performed
from an intensive care unit (ICU) perspective.
However, a substantial number of affected sub-
jects are never admitted to an ICU, making our
understanding of this patient group incomplete.2–
11 In order to describe the characteristics, ICU
treatment rate, treatment intensity and outcome of
patients with community-acquired severe sepsis
in Haukeland University Hospital, we undertook
an observational study with enrollment from dif-
ferent units. Our hypothesis was that a consider-
able number of these patients also in our hospital
are handled outside an ICU. We have in this way,
to the best of our knowledge, for the first time
compared treatments administered to ICU vs.
non-ICU-treated individuals with severe sepsis.
Methods
Definitions
Severe sepsis was defined by the presence of
sepsis in conjunction with organ dysfunction.12
We used a modified selection of the expanded
diagnostic criteria presented by Levy et al. as
criteria for organ dysfunctions:13
• Arterial hypotension (systolic blood pressure
<90 mmHg or a mean arterial pressure
decrease >40 mmHg)
• Hypoxemia (SpO2 <90% while breathing air)
• Acute oliguria (urine output <0.5 ml/kg/h for
at least 4 h)
• Increase in s-creatinine >50 lmol/l
• Lactic acidosis (pH <7.30 and s-lactate
>4.0 mmol/l)
• Thrombocytopenia (platelet count <100 9 109/
l or a 50% reduction ≤3 days)
• Hyperbilirubinemia (s-bilirubin >70 lmol/l)
• Altered mental status (Glasgow Coma Scale
<15 or if known cognitive impairment; clinical
judgment)
Setting
This was a 1-year prospective, case-defined
observational study of patients with
community-acquired severe sepsis in a tertiary
care referral center and teaching hospital in
western Norway. Since 2003, the hospital has
had common guidelines for initial handling of
sepsis and severe sepsis. Full details of the
study setting, inclusion criteria and data collec-
tion have been provided elsewhere.14 Patients
were included consecutively from 1 January
through 31 December 2008. Enrollment took
place in the following units: (1) a 10-bed gen-
eral ICU at the Department of Anaesthesia and
Intensive care; (2) a 12-bed combined ICU/non-
ICU ward at the Department of Cardiology,
composed of four fully equipped ICU beds and
eight surveillance beds; and (3) a 13-bed ward
at the Division for infectious diseases, Depart-
ment of Medicine. Two of the 13 beds at the
medical ward had surveillance facilities offering
intra-arterial blood pressure monitoring and
treatment with vasoactive drugs as well as non-
invasive ventilation support. The non-ICU beds
at the Department of Cardiology had the same
facilities.
The three units are run by different clinical
departments in separate units. They also differ
with regard to nurse to patient ratio which was
0.43 in the Medical Ward, 0.71 in the combined
unit and 1.0 in the general ICU. The latter had a
dedicated on-call by intensivists, different from
the other two units with on-calls from their
respective departments. Only the general ICU
had the possibility of giving continuous renal
replacement therapy. In the current investiga-
tion, patients were separated into two cohorts
according to their highest level of care, that is, if
they were receiving treatment in an ICU bed at
any time during their hospital stay or not (ICU
vs. non-ICU level, Fig. 1).
Patient selection
All subjects transferred from the emergency
department (ED) to any of the three units were
screened for eligibility. Patients ≥16 years of age
hospitalized due to community-acquired infec-
tion, including patients transferred from affili-
ated hospitals, were included if they developed
severe sepsis within 24 h of admission to the
primary institution. Unit affiliation was decided
in the ED upon the attending physicians’ discre-
tion, based on clinical risk stratification and
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need for advanced organ support aided by the
hospital’s sepsis guidelines.
Data collection
Data were collected prospectively on a daily
basis in the three participating units. Data from
the ED and from affiliated hospitals before
transfer were registered retrospectively. During
surveillance of patients, variations in vital
parameters, urine output and biochemical analy-
ses were followed. Use of non-invasive or inva-
sive ventilation support and administration of
antimicrobial therapy, intravenous fluids, glu-
cose-insulin, vasoactive drugs and corticos-
teroids was registered. Surgical treatment in
relation to severe infection was documented.
Simplified Acute Physiology Score II (SAPS II)
was calculated in patients treated in an ICU-
bed. Finally, total hospital and ICU length of
stay (LOS) as well as hospital outcome were
recorded. Hospital survivors were followed up
for 5 years after discharge.
Statistical methods
Descriptive statistics for continuous variables
are presented as mean  standard deviation
(SD) or median and interquartile range (IQR)
and compared between groups with Student’s
unpaired t-test or the exact Mann–Whitney U-
test when appropriate. Descriptive statistics for
categorical variables are compared between
groups with the exact Pearson’s chi-squared test
(v2) with odds ratios (ORs) and 95% confidence
intervals (CIs). Binominal logistic regression
analysis was performed, both simple (unad-
justed) and multiple, to adjust for confounding
variables. Variations in effects (ORs) were eval-
uated to control for influence of collinearity
among the explanatory variables. All variables
with a pre-specified plausible relationship with
the dependent variable were included;
both variables with a relationship in univariate
analysis (P ≤ 0.05) and those which did not
reach statistical significance. Backward stepwise
selection was used to identify a final simplified
model including only predictors significant at
the 0.05 level. Results are reported as ORs with
95% CIs and P-value from the likelihood ratio
(LR) test. Hosmer–Lemeshow’s goodness-of-fit
test is reported for the final model. Survival is
illustrated by Kaplan–Meier plots and compared
between groups with log rank tests. Multivari-
able survival analysis was performed using
Cox’s regression model, and results are
Fig. 1. Flowchart of the inclusion process and separation into study cohorts.
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presented as hazard ratios (HRs) with 95% CIs
and P-value from the LR test. All tests were
two-tailed and a P-value ≤0.05 was considered
statistically significant. The statistical analyses
were performed using SPSS software (IBM
SPSS Statistics, version 22.0; Chicago, IL, USA).
Ethical approval
This study was initially approved by the privacy
ombudsman at Haukeland University Hospital
as a quality study in 2007. Later, an extended
ethical application was sent to The Regional
Committee for Medical and Health Research
Ethics in Western Norway, which was approved
(case number REK-West 2010/165).
Results
Baseline characteristics
In total, 220 cases with community-acquired
severe sepsis were identified, of which 107
were included in the ICU cohort and 113 in the
non-ICU cohort (Fig. 1). Baseline characteristics
and clinical presentation according to care level
is outlined in Table 1. There were no signifi-
cant differences in gender or age distribution,
but there was a tendency toward older age
among non-ICU patients. Presence of underly-
ing comorbidities was similarly distributed
with the exception of dementia. Limitations of
care were less frequent in the ICU cohort,
where five patients were given a do-not-resus-
citate order compared with 15 in the non-ICU
cohort (v2 OR 0.32 (0.11, 0.92), P = 0.034). The
number of fulfilled systemic inflammatory
response syndrome (SIRS) criteria at admission
did not differ.
Infection
The respiratory tract was the most frequent
focus of infection at both care levels (Table 1).
The majority of abdominal infections were
found in ICU patients (77%, v2 OR 4.10 (1.58,
10.66), P = 0.003), whereas genitourinary infec-
tions most often were found in non-ICU patients
(81%, v2 OR 0.21 (0.08, 0.53), P < 0.001). The
different occurrence of these two infections was
significant also in multivariable analysis.
Twenty-four out of 27 patients with soft tissue
infections were initially referred to non-ICU
level; however, nine cases were subsequently
transferred to an ICU. A confirmed pathogen
was detected in 60 vs. 69 patients in the ICU vs.
non-ICU cohort, respectively (v2 OR 0.81 (0.48,
1.39), P = 0.50).
Organ dysfunction
The median number of acute organ dysfunctions
was 3 and 2 in ICU and non-ICU patients,
respectively (IQR = 1 for both groups,
P < 0.001). Patients receiving intensive care had
a higher median s-creatinine and a lower urine
output level (Table 2). They also developed
more hypoxia, hypercapnia, hyperlactatemia and
severe acidosis. In addition, their mean arterial
blood pressure was lower. Average SAPS II
score among ICU-treated patients was 52  20
(95% CI (48, 56)). The distribution of acute
organ dysfunctions is shown in Table 3.
Treatment
Treatment is specified in Table 3. Consistently,
the intensity of treatment was significantly
higher at ICU level. Organ supportive therapy
was also documented at non-ICU level, how-
ever, only four non-ICU patients received both
vasoactive drugs and non-invasive ventilation.
Time from hospital admission to administration
of the initial dose of antimicrobial therapy was
longer at ICU level.
Resources and outcome
Median hospital LOS was 15 days at ICU and
9 days at non-ICU level (P = 0.001) (Table 4).
Median ICU LOS was 6 days for eligible
patients. The hospital case-fatality rate (CFR)
was higher in ICU compared with non-ICU
patients (35% vs. 16%, P = 0.002). ICU patients
also had a higher mortality rate after 1 year
(42% vs. 27%, P = 0.024), whereas 5-year mor-
tality rates were similar in the two cohorts (57%
vs. 58%, P = 0.892). Among patients admitted
to the medical ward but subsequently trans-
ferred to an ICU, the hospital CFR was 44%,
while it was 23% among non-ICU patients
receiving organ supportive therapy. Kaplan–
Acta Anaesthesiologica Scandinavica (2017)
4 ª 2017 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd
S. T. NYGARD ET AL.
Meier curves on hospital and long-term survival
after community-acquired severe sepsis, accord-
ing to the level of care during hospitalization,
are presented in Fig. 2A and B. By multiple Cox
regression, effect (HR; 95% CI; P-value) on mor-
tality after discharge in 165 hospital survivors
was found for increasing age (1.06 per year;
(1.04, 1.07); <0.001) and soft tissue infection
(0.15; (0.04, 0.60); 0.008), whereas not for gen-
der (1.31; (0.80, 2.14); 0.288), care level during
hospitalization (1.19; (0.70, 2.02); 0.514) or
other foci of infection (data not shown).
Table 1 Baseline characteristics of ICU and non-ICU-treated patients compared by logistic regression analysis.
Characteristics
All ICU non-ICU
Unadjusted models Fully adjusted model* Final model†
n = 220 n = 107 n = 113 OR 95% CI P OR 95% CI P OR 95% CI P
Gender
Male 117 59 58 1.00 Reference 0.571 0.271
Female 103 48 55 0.86 (0.51, 1.46)
Age, years
16–30 18 9 9 1.00 Reference 0.296 1.00 Reference 0.677
30–45 22 13 9 1.44 (0.41, 5.07) 1.20 (0.29, 4.93)
45–60 36 21 15 1.40 (0.45, 4.36) 0.85 (0.22, 3.21)
60–75 68 34 34 1.00 (0.35, 2.83) 0.70 (0.20, 2.44)
75 76 30 46 0.65 (0.23, 1.83) 0.51 (0.13, 1.95)
Median (IQR) 67 64 (25) 69 (23) 0.056‡
Mean ± SD 64 62 ± 19.2 66 ± 19.6
Comorbidity
Hypertension 91 48 43 1.32 (0.77, 2.27) 0.305 1.60 (0.82, 3.13) 0.168
Cardiovascular 107 48 59 0.75 (0.44, 1.27) 0.275 0.90 (0.43, 1.89) 0.785
Pulmonary 61 33 28 1.35 (0.75, 2.45) 0.315 1.32 (0.67, 2.60) 0.417
Diabetes 38 17 21 0.83 (0.41, 1.67) 0.597 1.05 (0.45, 2.44) 0.914
Malignancy 31 18 13 1.56 (0.72, 3.36) 0.257 1.31 (0.54, 3.20) 0.554
Dementia 17 2 15 0.12 (0.03, 0.56) 0.001 0.16 (0.03, 0.89) 0.014 0.15 (0.03, 0.73) 0.005
Psychiatric 51 23 28 0.83 (0.44, 1.56) 0.564 0.67 (0.32, 1.41) 0.290
Substance
abuse
31 17 14 1.34 (0.62, 2.86) 0.456 0.91 (0.38, 2.22) 0.843
Other 74 34 40 0.85 (0.49, 1.49) 0.570 0.87 (0.45, 1.68) 0.676
SIRS criteria §
0 7 3 4 0.86 (0.18, 4.07) 0.549 0.93 (0.13, 6.48) 0.800
1 20 12 8 1.72 (0.64, 4.62) 1.54 (0.50, 4.76)
2 57 31 26 1.37 (0.70, 2.67) 1.26 (0.58, 2.74)
3 88 41 47 1.00 Reference 1.00 Reference
4 44 18 26 0.79 (0.38, 1.65) 0.68 (0.29, 1.58)
Missing 4 2 2 1.15 (0.15, 8.51) 0.74 (0.09, 6.33)
Infection
Respiratory 115 54 61 1.00 Reference 0.001 1.00 Reference 0.011 1.00 Reference 0.004
Genitourinary 31 6 25 0.27 (0.10, 0.71) 0.32 (0.11, 0.89) 0.30 (0.11, 0.81)
Soft tissue 27 15 12 1.41 (0.61, 3.28) 1.20 (0.48, 2.99) 1.35 (0.58, 3.18)
Abdominal 26 20 6 3.77 (1.41, 10.06) 3.50 (1.16, 10.58) 3.40 (1.27, 9.11)
Endocarditis 12 6 6 1.13 (0.34, 3.71) 1.30 (0.35, 4.77) 1.61 (0.34, 3.92)
Bacteremia 5 3 2 1.69 (0.27, 10.52) 1.79 (0.25, 12.59) 1.53 (0.25, 9.51)
CNS 4 3 1 3.39 (0.34, 33.55) 6.19 (0.51, 75.38) 5.76 (0.44, 74.82)
Data presented are number of patients compared by logistic regression analysis, unless otherwise specified. ICU intensive care unit, OR odds
ratio, CI confidence interval, p P-value, SD standard deviation, IQR interquartile range, SIRS systemic inflammatory response syndrome, CNS
central nervous system, DNR do-not-resuscitate. *Hosmer and Lemeshow’s chi-square test of fit = 8.02, df = 8, P = 0.431. †Hosmer and
Lemeshow’s chi-square test of fit = 1.51, df = 5, P = 0.912. ‡Mann–Whitney U-test. §At hospital admission. All patients fulfilled criteria for
severe sepsis with 2 SIRS criteria within 24 h of hospitalization.
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Discussion
In this prospective observational study, half of
the subjects with community-acquired severe
sepsis never received treatment in an ICU. They
developed less organ dysfunctions, and hence
used less hospital resources than ICU-treated
patients. While their hospital mortality was
low, overall 5-year mortality rates were similar
in the non-ICU and ICU cohorts. Increasing age,
not care level during hospitalization, had inde-
pendent impact on long-term survival in multi-
variable analysis.
An objective of our study was to describe the
ICU treatment rate of patients with community-
acquired severe sepsis in our hospital. However,
inclusion was restricted to three units. In a pre-
vious hospital survey, we had found that only
5% of patients with community-acquired severe
sepsis were treated outside these units (unpub-
lished results). Hence, we consider our current
inclusion process to be an acceptable modifica-
tion of hospital-wide screening.
All of the investigated units in our study had
some sort of surveillance facility and offered
treatment with vasoactive drugs and ventilation
support, although at different levels. One may
suspect that patients receiving organ supportive
therapy in our non-ICU cohort would have been
admitted to an ICU in a hospital with different
organization. However, opposing our ICU treat-
ment rate correlates to the upper fraction of pre-
vious results.2–6 To the best of our knowledge,
other descriptions of treatment of severe sepsis
outside ICUs do not exist. This makes it difficult
to judge the external validity of our data.
Previous retrospective studies from the United
States and Australia have estimated ICU treat-
ment rates similar to our result.2–4 Another ret-
rospective US study found that only 23% of
their patients were admitted to an ICU, but this
was solely based on ED reports.5 In our study,
17% of patients initially admitted to a medical
ward were later transferred to an ICU. Previous
prospective sepsis investigations include a
Spanish multicenter observational study where
the majority of infections were community
acquired.6 Severe sepsis was identified in an
ICU in 32% of their subjects. Other prospective
studies that specify their proportion of ICU-trea-
ted sepsis have inclusion criteria that make
comparison with our study difficult.7–10
The characteristics of patients with severe sep-
sis treated outside ICUs have been described
Table 2 Vital signs and biochemical values in ICU and non-ICU-treated patients.
Characteristics
All ICU non-ICU
Pn Value n Value n Value
Vital signs
Temperature, Celsius * 213 38.1  1.5 103 37.7  1.5 110 38.4  1.3 0.001
Pulse, n per minute * 214 105  23.9 104 107  24.7 110 104  23.0 0.356
Respiratory rate, n per minute * 153 29  8.6 70 30  8.6 83 29  8.5 0.369
Mean arterial pressure, mmHg† 220 53  12.0 107 51  10.8 113 56  12.6 0.001
Diuresis, ml/h† 210 25 (38.3) 107 17 (35) 103 40 (46) <0.001
Biochemical values
White blood cell count, 109/l* 219 13.7 (9.8) 107 13.7 (9.3) 112 13.7 (11.1) 0.618
CRP, mg/l* 217 122 (225) 105 82 (235) 112 149 (221) 0.075
Platelet count, 109/l† 220 192 (132) 107 175 (133) 113 206 (121) <0.001
Lactate, mmol/l† 203 2.4 (2.6) 107 3.4 (4.3) 96 1.8 (1.5) <0.001
Creatinine, lmol/l† 220 140 (157) 107 182 (215) 113 117 (93) <0.001
Bilirubin, lmol/l† 173 13 (17) 99 14 (17) 74 12 (16) 0.204
Glucose, mmol/l† 217 4.9 (1.9) 107 4.5 (1.7) 110 5.4 (2.0) <0.001
pH† 212 7.33 (0.23) 107 7.19 (0.19) 105 7.41 (0.11) <0.001
pO2, kPa† 213 7.1 (2.1) 107 6.9 (2.3) 106 7.7 (2.4) 0.005
pCO2, kPa† 213 6.0 (3.0) 107 7.5 (3.9) 106 5.1 (1.6) <0.001
Data presented are means  standard deviation or medians with interquartile range, respectively, compared with Student’s unpaired t-test
or the exact Mann–Whitney U-test as appropriate. ICU intensive care unit, p P-value. *Value at admission. †Outermost value (highest/lowest
of registered values during surveillance of organ dysfunction).
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elsewhere.4,6,7,11 Patients at the wards have
been found to have higher age, more severe
comorbidities and less acute organ dysfunctions
than ICU patients. Similar to our results, the
Spanish observational study documented a
lower overall occurrence of abdominal infections
than many previous reports.6 Furthermore, we
showed that the majority of abdominal infec-
tions were found in ICU patients. These obser-
vations are in line with studies that have
noticed a high demand for intensive care and a
higher occurrence of nosocomial than commu-
nity-acquired sepsis in this infection cate-
gory.6,15,16
Noticeably, time to initial administration of
antibiotics was longer in our ICU cohort, but
further analyses did not point out an underlying
explanation (data not shown). However, at hos-
pital admission, there was a tendency toward a
higher proportion of incorrect suspected infec-
tious focus (P = 0.123), and similarly more cases
with no suspicion of infection at all (P = 0.094)
in this group. Altogether, we speculate that a
more complex and severe spectrum of symptoms
have necessitated immediate focus on other
therapeutic measures and investigative modali-
ties.
We found that ICU-treated patients with sev-
ere sepsis stayed a median of 6 days longer in
the hospital than non-ICU-treated patients. Sim-
ilarly, a retrospective study from the United
States found a difference of almost 8 days in
mean hospital LOS for ICU vs. non-ICU
patients.2 A retrospective Australian study
Table 3 Organ dysfunction and treatment in ICU and non-ICU-treated patients
Category All n = 220 ICU n = 107 non-ICU n = 113 P OR 95% CI
Acute organ dysfunction
Number of organ systems
1 27 6 21 <0.001 1.00 Reference
2 53 14 39 1.26 (0.42, 3.75)
3 71 35 36 3.40 (1.23, 9.43)
4 48 37 11 11.77 (3.80, 36.43)
≥5 21 15 6 8.75 (2.36, 32.47)
Organ system
Respiratory 173 97 76 <0.001 4.72 (2.21, 10.10)
Circulatory 162 85 77 0.067 1.81 (0.98, 3.34)
Renal 145 84 61 <0.001 3.11 (1.72, 5.62)
Metabolic acidosis 73 55 18 <0.001 5.58 (2.97, 10,49)
CNS 75 34 41 0.569 0.82 (0.47, 1.43)
Hematologic 11 6 5 0.763 1.28 (0.38, 4.34)
Hepatic 7 4 3 0.716 1.42 (0.31, 6.52)
Treatment
Any ventilation support 129 98 31 <0.001 28.80 (12.97, 63.97)
Non-invasive ventilation* 59 28 31
IPPV 70 70 0
Vasoactive drugs 105 80 25 <0.001 10.43 (5.60, 19,44)
Corticosteroids 39 29 10 <0.001 3.83 (1.76, 8.33)
Glucose-Insulin 86 66 20 <0.001 7.49 (4.02, 13.93)
Surgery 38 25 13 0.021 2.35 (1.13, 4.87)
Fluids, ml† 5200 (3500) 6000 (4675) 4625 (3500) 0.002
Antibiotics, hours‡ 2.7 (5.2) 3.5 (7.8) 2.0 (3.7) 0.011
Data presented are number of patients compared with chi-square test unless otherwise specified. ICU intensive care unit, p P-value, OR odds
ratio, CI confidence interval, IPPV intermittent positive pressure ventilation. *Non-invasive ventilation as highest level of ventilation support.
†Fluid resuscitation (median with IQR) during the first 24 h after hospital admission, compared with the Mann–Whitney U-test. N = 187
patients included in analysis, 85 in ICU group and 102 in non-ICU group. ‡Time to administration of first antibiotics (median with IQR), com-
pared with the Mann–Whitney U-test. N = 209 patients included in analysis; two patients died before antibiotics was administered, six
patients from affiliated hospitals had no information about timing, and in one patient, the time of administration was not documented. In
addition, two outliers in non-ICU group with administration of the initial dose >100 h after hospital admission was excluded from analysis.
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calculated a larger difference, but their popula-
tion included subjects without organ dysfunc-
tion.4 Our 6 days median ICU LOS is in the
lower range of previous observations, probably
due to our exclusion of nosocomial severe sep-
sis.2,15,17–19 A recent prospective study of com-
munity-acquired early septic shock reports a
comparable mean ICU LOS of approximately
5 days.10
The crude hospital mortality rate for severe
sepsis was 27% in the single previous Norwe-
gian sepsis report, a retrospective nationwide
study from the year 1999.20 Mortality from
sepsis has been decreasing over time in several
investigations, so our status as a tertiary care
referral center may have influenced our present
25% hospital mortality rate to be in the upper
fraction of nationwide data.21–25 Relatedly, the
corresponding rate in the year 2008 was also
close to 25% in a retrospective study from an
Australian and New Zealand ICU database
including some high dependency units.26 Hospital
mortality was 16% in our non-ICU-treated
patients. This is lower than the 30%, 26% and
23% documented in non-ICU-treated severe sep-
sis cohorts from Australia, Spain and the United
Table 4 Length of stay and outcome in ICU and non-ICU-treated patients
Category
All ICU non-ICU
P OR 95% CIn value n Value n Value
Length of stay, median days
Hospital, total 220 11 (17) 107 15 (24) 113 9 (12) 0.001
ICU 107 6 (9)
Respiratory tract infection * 115 12 (14) 54 15 (15) 61 8 (11) 0.009
Genitourinary infection 31 8 (7) 6 20 (15) 25 7 (6) 0.004
Abdominal infection 26 14 (40) 20 17 (54) 6 12 (14) 0.700
Soft tissue infection 27 24 (33) 15 34 (38) 12 21 (24) 0.323
Case-fatality rates†
In-hospital 220 55 (25) 107 37 (35) 113 18 (16) 0.002 2.79 (1.47, 5,30)
28-days 220 54 (25) 107 36 (34) 113 18 (16) 0.003 2.67 (1.41, 5.10)
1-year 220 76 (35) 107 45 (42) 113 31 (27) 0.024 1.92 (1.10, 3.38)
5-year 220 127 (58) 107 61 (57) 113 66 (58) 0.892 0.94 (0.55, 1.61)
Data presented are medians with interquartile range and numbers with percentages in parentheses, compared with the Mann–Whitney U-test
or the chi-square test as appropriate. ICU intensive care unit, p P-value, OR odds ratio, CI confidence interval. *Endocarditis, bacteremia and
central nervous system infection not shown due to a low number of cases in these categories. †Registration from hospital admission, includ-
ing hospital deaths.
Fig. 2. Hospital and long-term survival after community-acquired severe sepsis. Kaplan–Meier curves illustrating (A) hospital survival in 220
patients and (B) 5-year survival after hospital discharge in 165 hospital survivors, compared across different levels of care (non-ICU vs. ICU) during
hospitalization. ICU intensive care unit.
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States2,4,6 We did not include patients with
nosocomial infection from units associated with
severe comorbidity like, for example, the depart-
ment of oncology. Furthermore, these studies
originate from the years 1995–2003 and a time-
related decline in mortality could have occurred.
Finally, our inclusion from a combined ICU/
non-ICU ward may have exerted favorable influ-
ence on mortality because of a better staffing
ratio and more skilled personnel serving the
non-ICU beds. On the contrary, our 35% hospi-
tal mortality at ICU level is similar to results
from both the current three studies as well as
other preceding observational studies of severe
sepsis.2,4,6,17,18,27 Part of the discrepancy in sur-
vival between our ICU and non-ICU cohort
when comparing with the previous literature
could be due to a different ICU admission
threshold in our hospital. However, prospective
studies on severe sepsis in ICU settings have
presented median or mean SAPS II values that
range from 45 to 56, corresponding to our ICU
cohort’s mean value of 52.15,17,27–30 A final
noticeable result concerning hospital outcome in
our study is the high CFR among patients who
were transferred to an ICU from the medical
ward. This could be explained by unexpected
deterioration of detected infections, or also be a
consequence of delayed recognition of severe
sepsis and secondary postponed admittance to
the appropriate level of care. Unfortunately, we
did not register the time to diagnosis of severe
sepsis and cannot comment any further on this
matter.
A recent publication has confirmed that com-
munity-acquired sepsis is independently associ-
ated with an increased risk of death for a long
period after hospitalization.31 It describes a
national population-based longitudinal cohort
of adults ≥45 years of age, where the 1-year,
2-year and 5-year all-cause mortality rates among
individuals with sepsis were 23%, 29% and
44%. Similarly, in our study, the 1-year mortal-
ity rate after severe sepsis was 27% and 42%,
and the 5-year mortality rate 58% and 57% in
patients treated at non-ICU and ICU level,
respectively. Our 1-year mortality rate in ICU
patients is comparable with other results.10,17,32
In the United States, further long-term survival
after severe sepsis has been surveyed in patients
≥65 years of age.24 Around 80% of the patients
in that study died within 5 years after a severe
sepsis episode. When we split our data at the
same age level, the resulting 5-year mortality rate
among patients ≥65 years was 77% in contrast to
35% in subjects <65 years (data not shown).
Out–of-hospital survival was significantly differ-
ent in our ICU and non-ICU cohorts by log rank
test, but care level during hospitalization did not
have independent impact in our multiple Cox
regression model. Comparably, long-term mor-
tality was unrelated to sepsis severity in a
recently published Danish investigation of com-
munity-acquired sepsis.33 Increasing age was, on
the contrary, associated with long-term mortality
in our study. Overall, there was only a tendency
toward a difference in median age between our
ICU and non-ICU-treated patients, however, the
lack of significance could be a matter of sample
size. Regardless of this, we believe the difference
in long-term survival among the two cohorts is
an indicator of appropriate allocation of our ICU
resources. After discharge, the ICU-treated hos-
pital survivors exhibited one half the mortality
rate when compared with non-ICU-treated sub-
jects, and were therefore probably less morbid at
baseline. Yet, the non-ICU cohort had signifi-
cantly lower hospital mortality, justifying their
level of treatment during hospitalization.
Major strengths of this study are the prospec-
tive design, inclusion throughout an entire year
to detect seasonal changes in infectious diseases,
and a long follow-up. Major limitations are the
sample size and that the inclusion of patients
was not performed hospital-wide. Although rare
in our hospital, some patients with community-
acquired severe sepsis may have been treated
outside the surveyed three units, leading to an
overestimated ICU rate. Finally, the acute organ
dysfunctions are insufficiently described as no
severity of disease classification system was used
at non-ICU level. This makes it difficult to com-
pare the quality of treatment across the two care
levels. Ideally, we should have obtained SOFA
scores prospectively for all patients.
In conclusion, half of the subjects with com-
munity-acquired severe sepsis in our hospital
never received ICU treatment. Still, use of low-
level organ supportive therapy outside the ICU
was considerable. Hospital mortality was
higher, whereas 5-year survival was similar
when comparing ICU with non-ICU patients.
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There is a need for additional studies of sepsis
with inclusion of patients from both inside and
outside the ICU. Future studies should use dis-
ease severity scoring systems in order to com-
pare the quality of treatment offered at different
levels of care.
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Although sepsis is the leading cause of death from infection, there are few population-level
epidemiological sepsis reports. The impact of sepsis-related deaths on all-cause hospital
mortality is insufficiently described, in particular in Europe where data are non-existent. The
objective of this study was to provide nationwide epidemiological results on sepsis hospitali-
zations in Norway and to estimate sepsis’ contribution to overall hospital mortality in a Euro-
pean setting.
Methods
We performed a retrospective study using data from the Norwegian Patient Registry and
Statistics Norway. The occurrence, patient characteristics and outcomes of sepsis hospitali-
zations during the years 2011 and 2012 were estimated and compared with Norwegian pop-
ulation data. Sepsis was defined as organ dysfunction caused by a dysregulated host
response to infection and identified with International Classification of Diseases 10th revision
codes.
Results
We identified 18 460 sepsis admissions occurring in 13 582 individuals. The annual popula-
tion incidence of hospitalized sepsis was 140 patients per 100 000 inhabitants; ranging from
10 to 2270 per 100 000 in different age groups and with statistically significant male predom-
inance in all adult cohorts. Hospital mortality for sepsis admissions was 19.4% and overall,
26.4% of the included patients died while hospitalized for sepsis. Sepsis related deaths con-
stituted 12.9% of all hospital fatalities, while hospitalizations with sepsis accounted for 1.0%
of the total number of admissions and 3.5% of the total admission days during 2011 and
2012.
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Conclusions
This study confirms that hospitalized sepsis is frequent in Norway and a major contributor to
hospital fatalities in a European setting. The incidence is higher among men than women.
Sepsis is in particular a disease of the elderly, and its impact on health-care will assumingly
continue to increase in parallel with an aging population. Improvements in treatment and
survival of sepsis could influence population mortality, and sepsis should receive greater
attention in official death statistics in the future.
Introduction
Sepsis is the leading cause of death from infection and a major public health concern in most
countries. Still, the epidemiology of this condition is insufficiently described. Population-level
results on the incidence of hospital-treated sepsis exist for only eight countries around the
world, including Norway as one of four European sites [1, 2]. The currently available Norwe-
gian study is however from the year 1999, and thus of uncertain validity as the occurrence and
outcome of sepsis has changed during the last decades [1, 3]. Hence, this study was conducted
to gain updated results on the epidemiology of sepsis hospitalizations in Norway. Furthermore,
a secondary objective was to investigate sepsis’ contribution to hospital fatalities, which previ-
ously has been surveyed in the United States (U.S.) only [4]. Since we were able to extract
information from all Norwegian hospitals, we present the first estimate of sepsis’ impact on
overall hospital mortality from complete nationwide data.
Materials and methods
This was a retrospective study combining hospitalization data from the Norwegian Patient
Registry (NPR) and population data from Statistics Norway [5, 6]. The years 2011 and 2012
were chosen because these were the most recent years from which complete data were available
when the study was conceived. The NPR is a national database run by the Norwegian Director-
ate of Health, containing information about all hospital admissions in Norway (patient data,
dates of hospitalization, type of hospital and department, vital status at discharge and Interna-
tional Classification of Diseases 10th revision (ICD-10) discharge codes). Reporting to the NPR
is mandatory. In the current study, a primary search throughout the years 2011 and 2012 was
performed by use of selected ICD-10 discharge codes for infections, systemic inflammatory
response syndrome (SIRS), sepsis by causative microbes, and septic shock (Table 1). In this
primary cohort, we then searched for the presence of up to eight additional ICD-10 discharge
codes indicating acute organ dysfunction. Sepsis was defined as life-threatening organ dys-
function caused by a dysregulated host response to infection, inspired by the Third Interna-
tional Consensus Definitions for Sepsis and Septic Shock [7]. Accordingly, the final study
cohort consisted of cases fulfilling one or several infection or sepsis related ICD-10 codes as
well as one or several codes for acute organ dysfunction (Fig 1).
The NPR database was used to obtain data regarding hospital stay (days), outcome (hospital
mortality), age and gender. Information about the total number and total duration of somatic
hospital stays in Norway during the years 2011 and 2012 was also collected from the NPR,
while national population data including total number of hospital deaths were retrieved from
Statistics Norway. The extracted patient data were transferred to a local database (FileMaker,
Inc, Pro 14.0; Santa Clara, CA, U.S.). In patients with more than five admissions during the
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Table 1. ICD-10 codes used in this study.





A21.7 Sepsis (generalized) tularemic
A22.7 Anthrax sepsis




A40 (.0, 1, 2, 3, 8, 9) Streptococcal sepsis





A48.3 Toxic shock syndrome
A54.8 Other gonococcal infections
B37.7 Candidal sepsis
J09 Influenza due to identified zoonotic or pandemic influenza virus
J10 Influenza due to identified seasonal influenza virus
J13 Pneumonia due to Streptococcus pneumoniae
J14 Pneumonia due to Haemophilus influenzae
J15 Bacterial pneumonia, not elsewhere classified
J18 (.0, 1, 2, 8, 9) Pneumonia, unspecified microbiology
J36 Peritonsillar abscess
J39 Other diseases of upper respiratory tract





N10 Acute tubulo-interstitial nephritis
O85 Puerperal sepsis
P36 Bacterial sepsis of newborn
R57.2 Septic shock
R65 (.0, 1, 9) Systemic Inflammatory Response Syndrome [SIRS] of infectious origin without
(.0) or with organ dysfunction (.1), or not further specified (.9)
T81.4 Infection following a procedure
Organ dysfunctions
R57 Shock
I50.9 Heart failure, unspecified
J80 Adult respiratory distress syndrome
J95 Postprocedural respiratory disorders
J96.0 Acute respiratory failure
N17 Acute renal failure
N99.0 Postprocedural renal failure
D65 Disseminated intravascular coagulation [defibrination syndrome]
D69 Purpura and other haemorrhagic conditions
(Continued )
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study period, the 6.th admission(s) were excluded from analyses. In the presentation of the
results, descriptive statistics for continuous variables are given as mean ± standard deviation
(SD) or median and interquartile range (IQR). Annual population incidence of hospitalized
sepsis was calculated as the number of patients experiencing one or more sepsis episode(s)
during 2011 and 2012, divided by the sum of the total number of inhabitants in Norway during
the same years. Population incidence by age and gender was compared by incidence rate ratios
(IRRs) with 95% confidence intervals (CIs). Survival is illustrated by Kaplan-Meier plots and
was compared between groups with log rank tests. A p-value 0.05 was considered statisti-
cally significant. The statistical analyses were performed using IBM SPSS Statistics (version
23.0; Aramonk, NY, U.S.); with the exception of the IRRs which were computed with MedCalc
for Windows (version 12.7; Ostend, Belgium).
Ethics approval
The study was approved by the Regional Committee for Medical and Health Research Ethics
in Western Norway, with a waiver of informed consent (case number 2014/1922).
Results
During the years 2011 and 2012, we identified 18 460 sepsis admissions occurring in 13 582
individuals in Norway. Hospitalizations with sepsis constituted 1.0% of the total number of
somatic hospital admissions (n = 1 767 535, Fig 1), and the annual population incidence of
hospitalized sepsis was 140 per 100 000 inhabitants. The incidence showed a great age depen-
dent increase; from 10 to 2270 patients per 100 000 inhabitants per year in different age groups
(Fig 2). The increase was more pronounced among men, who reached a maximum age-specific
annual incidence of 3430 per 100 000 inhabitants, while the corresponding rate for women
was 1880 per 100 000. However, significant gender disparities in incidence rates were found
across all adult age categories, starting from 20–29 years and upwards (S1 Table).
Characteristics of the study cohort are presented in Table 2. In total 82.8% of patients
were 60 years and the respiratory tract was the most common site of infection. Two or
more acute organ dysfunctions were documented in 14.7% of cases. The hospital mortality for
sepsis admissions was 19.4%, and overall during the study period 26.4% of the included
patients died while hospitalized for sepsis. Hospital mortality increased with age (Fig 3A, log
rank p< 0.001) and number of organ dysfunctions (Fig 3B, log rank p< 0.001).
The total number of hospital deaths in Norway during 2011 and 2012 was 27 705, and
deaths during hospital stays for sepsis constituted 12.9% of all hospital fatalities (Table 3). Fur-
thermore, hospitalizations with sepsis accounted for 3.5% of the total admission days during
the same period.
Discussion
This nationwide retrospective register-based study from 2011 and 2012 confirms that sepsis is
frequent and often fatal in Norwegian hospitals. The overall annual population incidence was
Table 1. (Continued)
ICD-10 code a Diagnosis
K72 Hepatic failure
E87.2 Acidosis
a Norwegian version, URL https://finnkode.ehelse.no/#icd10/0/0/0/-1
https://doi.org/10.1371/journal.pone.0187990.t001
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Fig 1. Diagram of the inclusion process.
https://doi.org/10.1371/journal.pone.0187990.g001
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140 per 100 000 inhabitants, showed a considerable age dependent increase, and was highest
among males. Sepsis admissions occupied 3.5% of the total admission days and had a mortality
rate of 19.4%. The observed number of deaths corresponded to 12.9% of the total number of
hospital fatalities during the study period, which to our knowledge is the first estimate of sep-
sis’ impact on overall hospital mortality from complete nationwide data.
The definition of sepsis was recently changed, and the term severe sepsis abandoned [7]. To
facilitate the interpretation of our results, we use the word sepsis as synonymous with the new
definition throughout the following discussion (i.e. life-threatening organ dysfunction caused
by a dysregulated host response to infection).
This is the second nationwide retrospective study of sepsis in Norway. Compared with pre-
vious data, the most notable difference is an almost threefold increase in the annual population
incidence which was estimated to 50 per 100 000 inhabitants in the year 1999 [3]. Other epide-
miological studies of sepsis in Norway is restricted to a single-center, prospective study per-
formed by the current authors in 2008 [8, 9]. Then, we detected an incidence of community
acquired sepsis of 50 per 100 000 inhabitants per year. It is plausible that these observations
reflect an ongoing trend of increasing sepsis occurrence, attributed to a growing number of
individuals at risk for severe infection [10–13]. Register-based studies are additionally likely
influenced by changes in coding patterns [14]. However, we included both codes for severe
infections, SIRS, sepsis by causative microbes, and septic shock in our primary search. Thus
influence of a potential shift in coding towards more frequent use of sepsis specific codes was
limited.
Throughout the last two decades there have been numerous international publications on
the epidemiology of sepsis. Yet, only eight countries have reported population-level incidences
Fig 2. Age-specific annual incidence of sepsis hospitalizations by gender in Norway 2011–2012. Significant gender differences in incidence rate
ratios were found starting from category 20–29 years and upwards, as shown in S1 Table.
https://doi.org/10.1371/journal.pone.0187990.g002
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and only four previous studies from Europe are performed with nationwide data [1–3, 11, 15,
16]. It is well known that there are large differences in previous reports of sepsis occurrence,
which partly may be explained by different study designs [1, 10, 17, 18]. Overall, our current
results are in line with two recent nationwide European studies as well as a population-based
study from China, while the most recent studies from the U.S. tend to report higher estimates
Table 2. Characteristics of patients with sepsis in Norwegian hospitals 2011–2012.
Characteristic N (% of total) a
Gender b
Male 7 327 (53.9%)
Female 6 255 (46.1%)
Age b
Median (IQR) 78 (21)
Mean ± SD 73 ± 18
ICD-10 codes found in the primary search c, d
Respiratory infections 12 932 (70.1%)
Soft tissue infections 899 (4.9%)
Genitourinary infections 822 (4.5%)
Abdominal infections 798 (4.3%)
Infection following a procedure 641 (3.5%)
Streptococcal sepsis 557 (3.0%)
Other sepsis (A41) 5 092 (27.6%)
SIRS (R65.0,1 or 9) 1 087 (5.9%)
Septic shock 735 (4.0%)
Other 159 (0.9%)
Organ dysfunctions c
Cardiovascular 8 944 (48.5%)
Respiratory 5 907 (32.0%)
Renal 4 597 (24.8%)
Hematologic 1 659 (9.0%)
Hepatic 436 (2.4%)
Metabolic 259 (1.4%)
Number of organ dysfunctions c
1 15 750 (85.3%)
2 2 198 (11.9%)
3 416 (2.3%)
 4 96 (0.5%)
Length of stay, days c
Median (IQR) 9 (12)
Mean ± SD 14 ± 19
Hospital mortality b
Total 3 620 (26.4%)
Male 2 021 (27.6%)
Female 1 565 (25.0%)
a if not otherwise specified.
b calculated from total number of patients hospitalized with one or more sepsis episode(s) (n = 13 582).
c calculated from total number of sepsis admissions (n = 18 460).
d in total 23 722 primary diagnostic codes were identified; patients could have more than one code.
https://doi.org/10.1371/journal.pone.0187990.t002
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[2, 11, 13, 15, 19–21]. This may reflect differences in health care systems as well as ICD-coding
practices [17]. Also, studies from the U.S. tend report incidence as the number of sepsis admis-
sions per unit of population older than18 years of age. If we use the same criteria, our corre-
sponding rate was e.g. 270 per 100 000 population in the year 2012.
We found a slight predominance of males in our study. There was in particular a higher
age-specific incidence of sepsis in males compared to females among the elderly, but signifi-
cant differences in incidence rate ratios were present in all adult cohorts. Possible explanations
for gender disparities in sepsis have been reviewed elsewhere [17], as similar age and gender
differences in sepsis occurrence have been observed [2, 15, 22–24]. In line with studies of
trends in sepsis epidemiology, our mean age of 72 years is higher than the equivalent of 58
years found in the previous nationwide report from Norway [3, 11, 23, 25]. The high average
age among our patient population furthermore corresponds to recent results [11, 13, 24]. The
elderly is especially predisposed to sepsis due to their high prevalence of chronic diseases, poly-
pharmacy, repeated hospitalizations, functional loss, malnutrition, common residencies in
long-term care facilities and, of course, due to age-related immunosenescence itself. Yet there
is no doubt that the registered hospitalizations among the oldest patients represent cases of
severe and resource demanding illness, these circumstances indicate that the elderly on aver-
age will have a greater number of diagnostic codes per hospital stay. This probably leads to a
greater chance of false positive sepsis cases by use of a code-based identification strategy, and
Fig 3. Hospital mortality for sepsis admissions in Norway 2011–2012. Kaplan-Meier plots illustrating hospital mortality for sepsis admissions in Norway
during 2011 and 2012, according to A. different age cohorts and B. number of affected organ systems.
https://doi.org/10.1371/journal.pone.0187990.g003
























2011 4 920 305 878 368 8 069 596 704 6 574 3 806 900 124 792 14 088 1 795
2012 4 985 870 889 167 10 391 601 456 7 008 3 667 016 139 679 13 617 1 791
Sum 9 906 175 1 767 535 18 460 1 198 160 13 582 7 473 916 264 471 27 705 3 586
If not otherwise specified, data represents number of cases (n =)
https://doi.org/10.1371/journal.pone.0187990.t003
Epidemiology and impact on all-cause mortality of sepsis in Norwegian hospitals
PLOS ONE | https://doi.org/10.1371/journal.pone.0187990 November 17, 2017 8 / 13
estimation of sepsis incidence is therefore especially prone to uncertainty in this subgroup of
patients.
Respiratory tract infections dominated among the infectious sources of sepsis in our
patients. Most of the previous register-based studies do not specify the distribution of infection
codes. However, similar results were found in the U.S. in 1995, and respiratory tract infection
was the most frequent infection category in recent prospective studies from both emergency
department and intensive care unit settings, as well as in our previous prospective study from
Norway [8, 22, 26, 27].
The number of organ dysfunctions among our patients is in the lower range compared to
previous nationwide figures from Spain and the U.S. [11, 13, 20, 21]. Case inclusion in these
retrospective studies was performed with fewer ICD-codes for infection and additional codes
for organ dysfunction. This may have resulted in selection of more severely ill patient popula-
tions [19, 28–30]. Of interest is a Swedish study that evaluated previously used approaches for
database extraction and found a lower presence of multiple organ dysfunctions among their
Swedish cohort than in two reference publications from the U.S. [16, 22, 23]. Nevertheless,
these findings do not reveal whether the apparent lower disease burden of sepsis in Scandina-
via actually is a true reflection of the disease, or a bias from a pattern of under-coding. Previous
prospective reports from Scandinavia have found a higher occurrence of multiple organ dys-
functions, but they are single-center studies from large University Hospitals [9, 26]. Prospec-
tive registration is inevitably superior in this setting, as it does not rely on compliance during
discharge coding. In addition, we excluded dysfunction of the central nervous system which
was present in 30–34% of the prospectively identified Scandinavian cases, due to lack of a dis-
tinct ICD-10 code.
Hospital mortality for sepsis admissions was 19.4% in our study, and 26.4% of the cohort
died while hospitalized for sepsis. This is consistent with other similar recent international
studies [13, 24]. Further, hospital mortality from sepsis in Norway has decreased from the pre-
vious estimation of 27.1%; despite an increase in mean age and a co-occurring decrease in the
mean number of admission days [3]. The latter has also been noted elsewhere [11, 13, 20].
We found that sepsis contributed to 12.9% of the total number of hospital deaths during the
study period. This is in contrast to the official cause of death statistics in Norway, where sepsis
is only superficially described in the annual report based on death certificates [31]. Similarly,
the corresponding report in the U.S. specifies sepsis to have caused 1.5% of all deaths in the
year 2014, while a retrospective investigation of hospital mortality showed that sepsis contrib-
uted to 1 in every 2 to 3 deaths [4, 32]. Both of these U.S. estimates include patients without
organ dysfunction. If we use the number of deaths found in our primary cohort (i.e. hospital
fatalities among the patients with selected codes for infection, sepsis or SIRS, n = 8186), our
corresponding number is 29.5%. With the exception of the mentioned retrospective report,
we found no previous literature on sepsis’ influence on total hospital mortality [4]. Other
researchers have used multiple causes of death data to assess the impact of sepsis on popula-
tion-level all-cause mortality [33–36].This approach underestimates sepsis-related mortality
compared with administrative datasets [37].
The aforementioned findings illustrate important difficulties in sepsis surveillance and
reporting. Several authors have reviewed approaches for code-based identification of sepsis.
Many have advised against limitation of discharge codes to diagnoses specific for sepsis and
septic shock. This has been found to yield more severely ill patient populations than prospec-
tive settings, and underestimate sepsis incidence [19, 28, 30]. Furthermore, a prospective
survey of sepsis in the medical emergency department at a Danish University Hospital re-iden-
tified only one in seven cases with a subsequent search based on ICD-codes [26]. The latter
results are undoubtedly notable, yet the prospective inclusion is subject to some limitations
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such as lack of verification of sepsis beyond the ED, and an unusual distribution of organ fail-
ure (65.1% had respiratory failure, denoted as SpO2 < 92% at admission, versus only 7.4–9.2%
with cardiovascular and renal failure). Just recently, a Swedish study evaluated three retro-
spective strategies including the previously used Norwegian method, against an intensive care
unit registry [38]. In this context, one should note that all of the evaluated methods were
designed prior to the introduction of specific codes for SIRS and sepsis with organ dysfunc-
tion. Although an incomplete amount of patients was identified by the Norwegian approach, it
was found to be the superior strategy [3, 22, 23].
Limitations
The main limitation of this study is its retrospective, code-based design [16, 17, 19]. In short, it
encumbers our results with uncertainties due to 1) its reliance on physicians’ ability to recog-
nize sepsis, 2) its susceptibility to under-documentation of sepsis per se and/or of accompa-
nying clinical findings, and, oppositely, 3) its susceptibility to identify false positive cases
because codes for organ dysfunction not necessarily originate from infection. Likewise, fatali-
ties could be caused by another co-occurring condition. Nevertheless, our results are similar to
contemporary results from a comprehensive manual review of all medical records of a Chinese
population [2]. Ideally we should have used a prospective design. This is unfortunately not fea-
sible on a national level, besides, recent data highlights that even case-based identification of
sepsis may be subject to high variability [39]. We confined our search to infections of a certain
severity in addition to the sepsis specific codes, and used a modest selection of acute organ dys-
functions based on the previously applied method in Norway. In light of the above discussion,
we therefore consider our current criteria for inclusion reasonable.
Conclusions
This nationwide study of sepsis in Norwegian hospitals shows an increasing occurrence com-
pared with previous data from 1999, while hospital mortality still is considerably high. Sepsis
should be recognized as an important contributor to hospital deaths, and receive attention in
official reports in the future. Improvements in treatment and survival could influence popula-
tion mortality. This is highly relevant, as there is reason to assume that the annual number of
hospitalizations and deaths from sepsis will continue to increase due to an aging population.
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